Skip to main content
NCBI home page
Journal of Zhejiang University. Science. B logoLink to Journal of Zhejiang University. Science. B
. 2021 Aug 15;22(8):609–632. doi: 10.1631/jzus.B2000808

Toll-like receptor 3 (TLR3) regulation mechanisms and roles in antiviral innate immune responses

Yujuan CHEN 1,2, Junhong LIN 1,2, Yao ZHAO 1,2, Xianping MA 1,2, Huashan YI 1,2,3,✉
PMCID: PMC8377577  PMID: 34414698

Abstract

Toll-like receptor 3 (TLR3) is a member of the TLR family, mediating the transcriptional induction of type I interferons (IFNs), proinflammatory cytokines, and chemokines, thereby collectively establishing an antiviral host response. Studies have shown that unlike other TLR family members, TLR3 is the only RNA sensor that is utterly dependent on the Toll-interleukin-1 receptor (TIR)‍-domain-containing adaptor-inducing IFN-‍β (TRIF). However, the details of how the TLR3-TRIF signaling pathway works in an antiviral response and how it is regulated are unclear. In this review, we focus on recent advances in understanding the antiviral mechanism of the TRIF pathway and describe the essential characteristics of TLR3 and its antiviral effects. Advancing our understanding of TLR3 may contribute to disease diagnosis and could foster the development of novel treatments for viral diseases.

Keywords: Toll-like receptor 3 (TLR3), Toll-interleukin-1 receptor (TIR)‍-domain-containing adaptor-inducing interferon-‍β (TRIF), Innate immune, Antiviral response

1 Introduction

Antiviral innate immune and inflammatory responses are the body's front lines of defense against viral infection (Yang and Shu, 2020). Rapid and effective recognition of microbial infection or danger signals from within the cell by the innate immune system is a premise for eliciting host responses to repulse the threats (Liu and Gack, 2020). The innate immunity of animals depends on pattern-recognition receptors (PRRs) that specifically recognize pathogen-associated molecular patterns (PAMPs) and then activate a signaling cascade triggering the type I interferon (IFN)‍- and interleukin-1 (IL-1)‍-mediated proinflammatory responses (Rai, 2020). The virus-perceiving PRRs mainly include Toll-like receptors (TLRs), retinoic acid-inducible gene-I (RIG-I)‍-like receptors (RLRs), and DNA sensors, such as cyclic guanosine mono-phosphate-adenosine monophosphate (GMP-AMP) synthase (cGAS), IFN-‍γ‍-inducible protein-16 (IFI16), and the recently identified heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNPA2B1) (Unterholzner et al., 2010; Sun et al., 2013; Wang Let al., 2019). TLRs are expressed mostly on the membranes of endosomes and lysosomes or on the surfaces of macrophages and dendritic cells (DCs), among other cell types, and are used to detect a wide range of microbial cell-wall-associated PAMPs and endosomal nucleic acids (Blasius and Beutler, 2010; Liu and Gack, 2020). RLRs are representative of cytoplasmic PRRs, which recognize both viral and host RNAs, even in sterile conditions via different mechanisms (Loo and Gale, 2011; Rehwinkel and Gack, 2020). Most RNA sensors reside in the endosome and cytoplasm, while PRR-mediated RNA sensing was recently shown also to occur in the nucleus and mitochondrion (Liuet al., 2018; Cao LLet al., 2019; Wang Yet al., 2019). In addition to PAMPs, PRRs can recognize tissue damage-associated molecular patterns (DAMPs) and play an essential role in promoting tissue repair and regeneration. However, they also cause numerous inflammatory diseases, such as metabolic disorders and autoimmune diseases (Mortazet al., 2017; Gonget al., 2020).

TLRs were the first PRRs to be identified and are the best characterized (Kawasaki and Kawai, 2014). The TLR family consists of 10 members (TLR1–TLR10) in humans and 12 members (TLR1–TLR9, TLR11‍–‍TLR13) in mice (Takeda and Akira, 2015). Each TLR is composed of an ectodomain (ECD) that mediates PAMP recognition, a transmembrane domain, and a cytoplasmic Toll-IL-1 receptor (TIR) domain responsible for downstream signaling (Kang and Lee, 2011). The signaling pathway of TLRs mainly includes the myeloid differentiation primary response protein 88 (Myd88)‍-dependent TLR signaling pathway and the TIR-domain-containing adaptor-inducing IFN-β (TRIF)‍-dependent TLR signaling pathway. The members of the TLR family selectively use adaptor proteins, including the TRIF (also called TIR-containing adapter molecule 1 (TICAM-1)), MyD88, transverse rectus abdominis musculocutaneous (TRAM) flap, and TIR-containing adaptor protein (TIRAP), to activate overlapping but distinct signaling pathways. These pathways initiate the transcriptional induction of mediators such as type I IFN and chemokines (Kawasaki and Kawai, 2014). TLR1, TLR2, and TLR5–TLR9 work via the Myd88-dependent TLR signaling pathway, TLR3 works via the TRIF-dependent TLR signaling pathway, and TLR4 triggers both pathways (Takeda and Akira, 2015).

TLR3 recognizes double-stranded RNA (dsRNA), which is a viral replication intermediate, and initiates downstream signal transduction, thereby up-regulating the expression of IFN-α/β and inducing antiviral protein (AVP) synthesis activity (Matsumotoet al., 2011). DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 (DDX1), DDX21, and DHX36, the members of the DExD/H-box helicase cytosolic sensors of dsRNA, share with TLR3, the TRIF for downstream type I IFN signaling (Zhang et al., 2011). TLR3 is the only receptor in the TLR family that depends entirely on the TRIF to induce IFN-‍β production (Yang and Shu, 2020). According to the different downstream products activated by TRIF, the TLR3-mediated signaling pathway can be divided into the TRIF-dependent nuclear transcription factor-‍κB (NF-‍κB) pathway and TRIF-dependent IFN-regulatory factor 3/7 (IRF3/7) pathway (Matsumoto et al., 2011). Once activated on the plasmalemma by exogenous dsRNA, TRIF interacts with tumor necrosis factor (TNF) receptor-associated factor 3 (TRAF3) and TRAF6 to trigger a series of cascade reactions. The mechanisms and negative regulation of TRIF are currently areas of active research that we emphasize in this review.

2 Characteristics and recognition of TLR3

2.1. Basic characteristics of TLR3

TLR3 is widely expressed in neurocytes, immune cells, fibroblasts, and various epithelial cells (Kulkaet al., 2004; Townet al., 2006; Fanget al., 2013; Buggeet al., 2017; Chen et al., 2019). Among immune cells, only myeloid DCs, macrophages, and mast cells (MCs) express TLR3. TLR3 localizes both at the cell surface and in endosomes in MCs and macrophages, but only in endosomes in myeloid DCs (Matsumotoet al., 2003, 2011; Agier et al., 2016). DCs are one of the most important immune cells that produce IFNs, including type I IFNs (α and β), which are associated with viral clearance (Matsumoto et al., 2003). TLR3 works in antigen-presenting DCs to induce lymphocyte-mediated antigen-specific immune responses (Matsumotoet al., 2020; Sotoet al., 2020). MCs have been reported to act as sentinel cells of innate immunity, extensively engaged in infection control and clearance (Piliponsky and Romani, 2018; Marshall et al., 2019). MCs express TLR3 molecules and other proteins associated with the cellular antiviral response, like IRF3, types I and II IFN receptors, and major histocompatibility complex (MHC) I (Witczaket al., 2020).

TLR3 consists of an ECD, a cytoplasmic TIR domain, a transmembrane domain, and two flanking regions, known as the leucine-rich repeat (LRR) C-terminal (LRR-CT) and N-terminal (LRR-NT) regions (Choeet al., 2005). The TLR3-transmembrane domain and ECD structures have been resolved through X-ray crystallography; nevertheless, the structure of a membrane-solvated full-length receptor remains inaccessible (Liuet al., 2008; Mineev et al., 2014). Molecular dynamics simulation has demonstrated that the stabilization of the TLR3-TIR dimerization interface relies on reciprocal contact between the αC and αD helices of one subunit and the αC helix and BB loop of the other (Patraet al., 2020). As a highly conserved region in the TIR domain, the BB loop is essential for mediating interactions among TIR domain-containing proteins (Singh et al., 2014). In the TLR3 A795P homodimer, the individual subunits are tilted slightly toward each other, which influences the orientation of the BB loops on the homodimer and, in turn, the binding of the TIR domain of TRIF to the homodimer (Mahita and Sowdhamini, 2018).

2.2. Recognition of dsRNA by TLR3

2.2.1. Activation of TLR3

The common ligands of TLR3 exist on poly(I:C), dsRNA viruses (e.‍g., rotavirus (RV), respiratory syncytial virus (RSV), murine cytomegalovirus (MCMV)), and single-stranded RNA (ssRNA) virus (e.‍g., West Nile virus (WNV)) (Alexopoulouet al., 2001; Topping and Kelly, 2019; Uehata and Takeuchi, 2020). A recent report showed that endothelial TLR3 could also detect extracellular dsRNA that is secreted from highly metastatic tumors (Tavora et al., 2020). TLR3 exists as a monomer and a membrane receptor in resting cells, and dimerizes only when bound to ligands via its ECD (Botos et al., 2009). The TLR3 ECD is formed by 23 LRRs, and the crystal structure resembles a sizeable horseshoe-shaped solenoid (Botos et al., 2009). Binding of the ECD domain of TLR3 to dsRNA requires an acidic environment (Leonard et al., 2008). As TLR3 functions mainly in the endosomes, several mechanisms have been suggested to account for delivery of extracellular TLR3-activatory dsRNA molecules into endosomes (Tabeta et al., 2006; Barton and Kagan, 2009; Pelkaet al., 2018). Mainstream theories include the uptake of apoptotic bodies from infected cells (Salio and Cerundolo, 2005), clathrin-dependent endocytosis (Itoh et al., 2008; Watanabe et al., 2011), formation of dsRNA complexes with antimicrobial peptide LL-37 (Singh et al., 2013; Takahashi et al., 2018), and autophagic uptake of dsRNA from the cytosol and trafficking to endosomes with inhibited lysosomal degradation (Søreng et al., 2018; Galluzzi and Green, 2019; Hase et al., 2020). Whether TLR3 can be activated from the cell surface is still unknown.

2.2.2. Structural basis of TLR3

When TLR3 associates with dsRNA, a dsRNA-TLR3 signaling complex composed of one dsRNA and two TLR3 molecules is formed (Liu et al., 2008; Peisley and Hur, 2013). The molecular structure of a signaling unit (SU) shows that dsRNA ligands bind two regions, one at the C-terminus (LRR19–LRR21) and the other near the N-terminus (LRR-NT and LRR1–LRR3) (Gaoet al., 2015). TLR3 binds with ligands exclusively via surface contacts (mainly hydrogen bonding and electrostatic interactions), while the protein–protein interactions occur only at the LRR-CT in the TLR3-dsRNA complex (Gao et al., 2015). Mutational analysis of human TLR3 has revealed that His39, His60, and His108 residues at the N-terminus, and His539 and Asn541 residues at the C-terminus, interact with dsRNA. The C-terminal dimerization site is critical for dsRNA binding and TLR3 signaling (Liu et al., 2008; Wang Yet al., 2010). Gao et al. (2015) found a weak dimer interface at the TLR3 ECD C-terminal site, which is required for effective dsRNA binding, and Pro680 is crucial for maintaining the dimer interface.

Studies have shown that, like TLR9, once within endosomes, TLR3 is cleaved by several cathepsins within its ECD because the full-length (non-cleaved) proteins are unable to form contacts with one another essential for receptor dimerization (Ewaldet al., 2011; Fitzgerald and Kagan, 2020). The cleaved fragments remain associated with each other, and both are important for the inflammatory activity of TLR9/3 (Fitzgerald and Kagan, 2020). However, more research is required to clarify the type of cathepsins required for cleaving TLR3 and how TLR3 is proteolytically processed. Furthermore, Luo et al. (2012) demonstrated that lateral SU clustering is necessary for productive TLR3 signaling. Three neutralizing Fab fragments (Fab15, Fab12, and Fab1068) of three antibodies prevent the lateral clustering of SUs along the length of the dsRNA ligand, resulting in antagonism towards TLR3 signaling. This indicates that lateral clustering of SUs is necessary for TLR3 signal transduction. The structure of the TLR3-dsRNA signaling complex is shown in Fig. 1.

Fig. 1. Structure of the human TLR3-dsRNA complex and three crucial interaction sites (Gosu et al., 2019). Individual chains of the TLR3 complex are shown in white (TLR3) and cyan (TLR3*). dsRNA, hydrogen bonds, and mutant residues are shown in orange, green, and magenta, respectively. For clarity, only the TLR3* N- and C-terminal interaction sites of dsRNA (46 bp) binding are shown. TLR: Toll-like receptor; dsRNA: double-stranded RNA.

Fig. 1

Open in a new tab

2.2.3. Structural basis of dsRNA

The minor groove, which contains degenerate sequence information, and the phosphate backbone are the main determinants of dsRNA binding to receptors (Doyle and Jantsch, 2002; Leonard et al., 2008). The major groove, which contains sequence-specific information, is a common site of double-stranded DNA (dsDNA)‍–‍protein interaction (Pabo and Sauer, 1984). Since dsRNA is also found in many cellular RNAs, three mechanisms have been proposed to be responsible for discrimination between viral and cellular dsRNAs by TLR3. First, the endosomal location of the TLR3 ECD restricts access of cellular dsRNAs to TLR3 (Sioud, 2006). Second, the presence of modified nucleotides such as N-methyladenosine and 2-thiouridine provides an additional physicochemical specificity for TLR3 to discriminate between self and non-self dsRNAs (Karikóet al., 2005). Third, TLR3 requires dsRNA to be longer than 40 bp for robust stimulation, which helps avoid inappropriate recognition of some cellular small interfering RNAs (siRNAs), microRNAs (miRNAs), or ssRNAs with short hairpin structures (Leonard et al., 2008). Other studies, however, showed that exogenously introduced 21-bp siRNA can also stimulate TLR3, suggesting that a high dose of RNA may compensate for the low-affinity interaction with short dsRNA (Karikóet al., 2004; Kleinmanet al., 2008). This evidence suggests that dsRNA length is not an absolute criterion used by TLR3 for self and non-self discrimination, but rather a relative condition that can be scaled by the abundance of RNA and receptors in the cell (Peisley and Hur, 2013). How shorter dsRNA ligands (21–39 bp) activate TLR3 signaling remains to be determined. It is also unclear how dsRNA ligands longer than 90 bp are sensed, which may induce higher-order oligomerization of the receptor (Luo et al., 2012).

2.2.4. Relevant proteins

TLR3 presents a K63-linked poly-ubiquitination at K831 by the E3 ubiquitin ligase tripartite motif-containing protein 3 (TRIM3), which is located mainly in the Golgi apparatus (Liet al., 2020). Then, the polyubiquitinated TLR3 is distributed to endolysosomes to sense viral dsRNA and trigger an antiviral response. The cytoplasmic TIR domain of TLR3 is tyrosine-phosphorylated upon ligand binding (Sarkaret al., 2003). Bruton’s tyrosine kinase (BTK) was reported to phosphorylate the cytoplasmic domain of TLR3, particularly the critical Tyr759 residue (Leeet al., 2012).

Cluster of differentiation (CD14), a class-A scavenger receptor, and clathrin-mediated endocytic pathways participate in cellular uptake of extracellular dsRNA (Lee et al., 2006; Itohet al., 2008; Limmon et al., 2008). However, a recent report indicated that human CD14 acts as a co-receptor only to human TLR9, not to TLR3, TLR7, or TLR8 (Weberet al., 2012). Mex3 RNA-binding family member B (Mex3B), an RNA-binding protein, is reportedly involved in the process of presenting endocytosed dsRNA to TLR3 in intracellular compartments (Yanget al., 2016; Zhuet al., 2016). Mex3B acts as a co-receptor of TLR3 in response to dsRNA, promoting dsRNA binding with endosomal TLR3 and proteolytic processing of TLR3 (Yang et al., 2016; Zhu et al., 2016). The zinc-finger FYVE domain-containing protein ZFYVE1 was revealed to promote the binding of TLR3 to poly(I:‍C) by associating with the ECD of TLR3 via its FYVE domain (Zhong et al., 2020). Ectopically expressed ZFYVE1 binds to the poly(I:C), and thus enhances the binding of TLR3 to poly(I:C) (Yamashita et al., 2012; Zhong et al., 2020). The relationship between Mex3B and ZFYVE1 in regulating the TLR3-mediated response is unclear. Luoet al. (2020) demonstrated that the Sh2 domain-containing leukocyte protein (SLP) adaptor is the universal TLR adaptor for TLR2, TLR3, TLR4, and TLR9, and the C-terminal Src kinase (CSK)‍-interacting membrane protein (SCIMP) presents Lyn and other effectors, such as Csk, Gdb2, and Slp65, to TLRs during cellular activation.

3 TLR3-TRIF signaling pathway

3.1. Overview of TLR3-TRIF signaling pathway

Upon activation, TLR3 recruits TRIF to trigger a downstream signaling cascade (Matsumotoet al., 2011). Unlike other TLR family members, TLR3 is utterly dependent on TRIF (Yang and Shu, 2020). The TLR3-TRIF signaling pathway involves signal transduction by TRAF3/6, TRAF family member-associated NF-‍κB activator (TANK)‍-binding kinase 1 (TBK1), inhibitor of κB (IκB) kinase-related kinase-ε (IKK-‍ε; also called IKK-i), receptor-interacting protein-1 (RIP-1), and NF-κB-activating kinase (NAK)-associated protein 1 (NAP1). This signaling pathway ultimately activates transcription factors, namely IRF3/7, NF-κB, and the activator protein 1 (AP-1), thus mediating the production of type I IFNs, proinflammatory cytokines, and chemokines, respectively, following TLR3 activation. Phosphoinositide 3-kinase (PI3K), p38-mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK) are also activated by TLR3 signaling (Schröder and Bowie, 2005). TLR3-induced MAPKs are responsible for activating AP-1, and PI3K is crucial for full phosphorylation and activation of IRF3 (Ameyar et al., 2003; Sarkaret al., 2004). Ubiquitination and phosphorylation play an indispensable role in the fine-tuning of the TLR3 signaling cascade. The general scenario of the TLR3-TRIF signaling pathway is described in Fig. 2a.

Fig. 2. Mechanism of the Toll-like receptor 3 (TLR3)-Toll-interleukin-1 receptor (TIR)-domain-containing adaptor-inducing interferon-β (IFN-β) (TRIF) signaling pathway and structure of human TRIF. (a) Mechanism of the TLR3-TRIF signaling pathway. After double-stranded RNA (dsRNA) activates endosomal TLR3, TRIF transiently colocalizes with TLR3; it dissociates from the receptor and forms a speckle-like structure that relocalizes with downstream-signaling molecules such as tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2), TRAF6, and receptor-interacting protein-1 (RIP-1) (Funami et al., 2004, 2007). Then, with the cooperation of TRAF3, TRAF family member-associated nuclear transcription factor-κB (NF-κB) activator (TANK)-binding kinase 1 (TBK1), inhibitor of κB (IκB) kinase-related kinase-ε (IKK-ε; also called IKK-i), and NF-‍κB-activating kinase (NAK)-associated protein 1 (NAP1), this signaling pathway ultimately activates transcription factors, namely IFN-regulatory factor 3/7 (IRF3/7), the TRIF-dependent NF-κB, and the activator protein 1 (AP-1), thus mediating the production of type I IFNs, proinflammatory cytokines, and chemokines, respectively. (b) Schematic structure of human TRIF. TRIF consists of an N-terminal protease-resistant domain (1-153 amino acids (aa)), an intermediate disordered proline-rich region (154-392 aa), a TIR domain (393-545 aa), and a C-terminal region (containing a RIP homotypic interaction motif (RHIM) domain, 661-699 aa) (Mahita and Sowdhamini, 2017). The disordered region between the N-terminal domain and the TIR domain contains binding sites for many downstream proteins such as TBK1, TRAF2 (332-336 aa), and TRAF6 (248-‍256 aa) (Sasai et al., 2010). The physical association between TRAF3 and TRIF is controversial (Nguyen et al., 2014). ZCCHC3: zinc finger CCHC-type containing 3; WDFY1: WD-repeat- and FYVE-domain-containing protein 1; TRIM23: tripartite motif-containing protein 23; LUBAC: linear ubiquitin chain assembly complex; RNF166: ring finger protein 166; HECTD3: E6-associated protein carboxyl terminus domain containing 3; Nedd4l: neural precursor cell expressed developmentally down-regulated 4-like; MIB: mind bomb; RNF128: RING finger 128; USP2b: ubiquitin-specific protease 2 isoform b; CYLD: conserved cylindromatosis; OTUD1: termed OTU domain-containing protein 1; PI3K: phosphoinositide 3-kinase; NEMO: NF-κB essential modifier; MAPK: p38-mitogen-activated protein kinase; FLIP: viral FLICE-like inhibitory protein.

graphic file with name JZhejiangUnivSciB-22-8-609-g002a.jpg

graphic file with name JZhejiangUnivSciB-22-8-609-g002b.jpg

Open in a new tab

The TRIF gene of humans is located on chromosome 19p13.3 and encodes 712 amino acids, making it much larger than the other TIR domain-containing linker proteins (Mahita and Sowdhamini, 2017). TRIF consists of an N-terminal protease-resistant domain (1–153 amino acids (aa)), an intermediate disordered proline-rich region (154–392 aa), a TIR domain (393–545 aa), and a C-terminal region (containing an RIP homotypic interaction motif (RHIM) domain, 661‍–699 aa) (Mahita and Sowdhamini, 2017) (Fig. 2b). The N-terminal region is involved in TRIF-mediated IRF3 activation, the C-terminal region is crucial for NF-‍κB activation and apoptosis, while the TIR domain is essential for binding to TLR3 (Tatematsu et al., 2010; Kumeta et al., 2014; Patra et al., 2020). The disordered region between the N-terminal domain and the TIR domain contains binding sites for many downstream proteins such as TBK1, TRAF2 (332–336 aa), and TRAF6 (TRAF6-binding motif 2 (T6BM) domain, 248–256 aa) (Sasaiet al., 2010). Mahita and Sowdhamini (2017) proved that the N-terminal domain binds to the BB-loop region of the TIR domain to prevent TLR3 homodimerization. The physical association between TRAF3 and TRIF has always been controversial. Many conflicting data about their physical association have been reported (Sasai et al., 2010). However, a recent report indicated that the 21 amino acid sequences (160–181 aa) from the amino-terminal half of TRIF are crucial for the TRAF3 association and modulating TRIF ubiquitination and degradation (Nguyenet al., 2014). TRIF with a 21-residue deletion (Δ160–181) inefficiently transactivated the IFN pathway, and its association with TRAF3 was weaker than that of wild-type (WT) TRIF (Nguyenet al., 2014).

Funami et al. (2016) demonstrated that 14-3-3-ζ acts as a novel component of the TRIF signalosome that functions in TLR3-mediated signaling. With the ablation of the TRIF signalosome in 14-3-3-ζ-knockdown cells, the synthesis of IFN and inflammatory cytokines decreased, and TLR3-mediated IRF3 translocation, as well as IkBα phosphorylation, was diminished. The identification of 14-3-3-ζ has shed new light on TRIF signaling.

3.2. Activation mechanism of the TLR3-TRIF signaling pathway

3.2.1. Recruitment of TRIF

TRIF is expressed at a low level in most tissues and cells, and exists diffusely in the cytoplasm of resting cells (Funami et al., 2016). After dsRNA activates endosomal TLR3, TRIF transiently colocalizes with TLR3; it dissociates from the receptor and alters its distribution profile from a diffuse cytoplasmic pattern to a speckle-like structure that relocalizes with downstream-signaling molecules (Funamiet al., 2004, 2007). Both TLR3 and TRIF contain a TIR domain, which is crucial to their interaction once TLR3 binds to the ligand (Oshiumiet al., 2003). The TIR domain of TLR3 has three highly conserved sequences, Box1, Box2, and Box3; Box2 constitutes the BB loop, which is crucial for binding downstream linker proteins (Singh et al., 2014). Unlike other TLRs, the BB loop in binding TRIF does not contain conservative proline residues, but is replaced by alanine, which is critical for binding TRIF. The TLR3 mutant A795H (TLR3 with Ala795His mutation) has lost the ability to bind to TRIF (Oshiumi et al., 2003).

A recent report indicated that WD-repeat- and FYVE-domain-containing protein 1 (WDFY1) acts as a critical adaptor protein during TLR3 recruitment of TRIF by associating with the TIR domain of TLR3 (Huet al., 2015). Their interaction depends on the tyrosine phosphorylation of TLR3. Zinc finger CCHC-type containing 3 (ZCCHC3) is also a critical component of the TLR3-TRIF signaling pathway, and facilitates the recruitment of TRIF to TLR3 after poly(I:C) stimulation (Zanget al., 2020). The N-terminal domain (1‍–300 aa) and C-terminal domain (300–404 aa) of ZCCHC3 are functional for its interaction with the N-terminal/TIR domains of TRIF and the TIR domain of TLR3, respectively.

3.2.2. TRIF-dependent activation of IRF3

IRF3 and another IRF family member IRF7, are known to be IFN regulatory factors (Wu and Chen, 2014). Both mediate the activation of NF-‍κB, but IRF3 is activated by the TRIF pathway and IRF7 by the MyD88 pathway (Kawai and Akira, 2010). In inactivated cells, IRF3 is phosphorylated to form the IRF3:IRF3 homodimer or the IRF3:IRF7 heterodimer, which enters the nucleus and leads to specific gene expression (Schmidet al., 2014). TRIF-mediated IRF3 activation is regulated by the protein kinases IKK-‍ε and TBK1. Activation may depend on upstream linker proteins, NAP1, TANK, and SINTBAD (similar to NAP1 TBK1 adaptor) (Tatematsu et al., 2010; Schmid et al., 2014). NAP1, TANK, and SINTBAD are similar in structure. NAP1 participates in the recruitment of IRF3 kinases to the N-terminal region of TRIF. TANK, as a binding ligand of TBK1, IKK-ε, and the TRAF family, is responsible for associating TRAF3 with TBK1 and IKK-ε (Ryzhakov and Randow, 2007).

TRIF is homo-oligomerized at the Pro434 residue in the TIR domain and the C-terminal region. The recruitment of TRAF3 by TRIF is essential for the activation of IRF3 (Funamiet al., 2008). TRAF3 undergoes a Lys63-linked poly-ubiquitination with the synergy of the E2 ubiquitin-conjugating enzyme Ubc13/Uev5 (Zenget al., 2009; Tsenget al., 2010). Then, ubiquitinated TRAF3 mediates oligomerization of TBK1 and IKK-ε via adaptor proteins such as TANK and NAP1 (Guo and Cheng, 2007; Tatematsu et al., 2010). TBK1 and IKK-ε are responsible for phosphorylation and activation of IRF3 (Zhouet al., 2020). The phosphorylated IRF3 dimerizes and translocates to the nucleus to initiate the transcription of the IFN-‍β gene (Honda et al., 2006). The activation, regulation, substrate, and function of TBK1 and IKK-ε remain to be elucidated.

c-Src tyrosine kinase is activated by dsRNA in human DCs, and then is recruited to TLR3 (Johnsenet al., 2006). In Src kinase-deficient cells, dsRNA-induced activation of IRF3 and activator of transcription 1 is abolished. Phosphorylation of TLR3 on tyrosine 759 increases in parallel to Src-dependent IFN-β production (Zhanget al., 2016). Serine/threonine kinase receptor-associated protein (STRAP) acts as a scaffold protein in TLR3-triggered signaling (Huhet al., 2017), and strongly interacts with TBK1 and IRF3 to enhance IFN-‍β production. K63-linked poly-ubiquitination of TRAF3 is promoted by overexpression of the E3 ligase ring finger protein 166 (RNF166) following Sendai virus (SeV) infection (Chenet al., 2015). The E6-associated protein carboxyl terminus domain containing 3 (HECTD3) also acts as an E3 ligase catalyzing this poly-ubiquitination during bacterial infection, but the exact function of HECTD3 during viral infection is poorly understood (Liet al., 2018). Neural precursor cell-expressed developmentally down-regulated 4-like (Nedd4l) promotes TRAF3-mediated signal transduction by catalyzing K29-linked ubiquitination at the C56 and C124 cysteine residues of TRAF3 (Liu, 2019). E3 ubiquitin ligases, mind bomb (MIB) and RING finger 128 (RNF128), promote the K63-linked poly-ubiquitination of TBK1 for its activation (Liet al., 2011; Songet al., 2016). In addition to E3 ligases, the deubiquitinating enzymes (DUBs) ubiquitin-specific protease 2 isoform b (USP2b) and the conserved cylindromatosis (CYLD) target TBK1 for K63-linked deubiquitination, and OTU domain-containing protein 1 (OTUD1) cleaves the K63-linked polyubiquitin chains from IRF3 (Luet al., 2018).

TRIF and two other adaptor proteins, stimulator of IFN genes (STING) and mitochondrial antiviral signaling (MAVS), mediate the recruitment of IRF3 via a conserved pLxIS motif, the same motif as that of IRF3 (ZhaoBY et al., 2016). The pLxIS motifs of the three adaptor proteins are phosphorylated by TBK1 or IKK-ε (Zhao BYet al., 2016). A recent paper demonstrated that phosphorylated TRIF, MAVS, and STING bind to a positively charged surface of IRF3 and thus recruit IRF3 for activation by TBK1 (Liu et al., 2015). TRIF is phosphorylated at its consensus motif S210/S212/T214 by TBK1, and TRIF S210 is the critical phosphorylation site for IRF3 activation.

3.2.3. TRIF-dependent activation of NF-κB

NF-κB is a central transcription factor crucial to innate and adaptive immunities, cell proliferation, apoptosis, and the stress response (Cartwrightet al., 2016). The p50/p65 heterodimer of NF-κB activates the expression of IFN-‍β and proinflammatory cytokines (Kawai and Akira, 2007; Kohlet al., 2019). The K63-linked polyubiquitin chains of RIP-1 and TRAF6 can recruit the transforming growth factor-‍β (TGF-‍β)-activated kinase 1 (TAK1)‍-TAK1-binding protein 2 (TAB2)-TAB3 complex via the ubiquitin-binding activity of TAB2/3, causing TAK1 autophosphorylation and activation (Yang and Shu, 2020). TAK1 activates the IκB kinase complex, which consists of the IKK-α and IKK-‍β kinases scaffolded by NF-‍κB essential modifier (NEMO), ultimately activating NF-‍κB or stimulating MAPK-mediated AP-1 transcriptional responses (Emmerichet al., 2013; Mitchellet al., 2016). RIP-1 associates with TRIF via the RHIM domain at the C-terminal of TRIF followed by RIP-1 interaction with TNF receptor-associated death domain (TRADD) protein. TRADD is an adaptor protein related to the ubiquitination of RIP-1, via the homotypic death domain (Meylan et al., 2004; Ermolaevaet al., 2008; Parket al., 2015). TRAF6 binds with the T6BM domain in the N-terminal region of TRIF to mediate NF-‍κB activation (Mahita and Sowdhamini, 2017). In addition, TRAF6 mediates the recruitment of meddlesome-associated TBK1 to stimulate the rapid induction of glycolysis following TLR3 activation (Tan and Kagan, 2019). The rapid glycolysis drives metabolic changes in the cell, resulting in an increased need for histone modifications related to durable transcriptional activities in the nucleus or enhanced protein synthesis and secretory activities associated with TLR3 signaling (Corcoran and O'Neill, 2016; Langstonet al., 2019).

The activation of the NF-‍κB signaling pathway is a sign of viral infection. Once NF-‍κB is activated, it up-regulates many cytokines and chemokines (such as TNF-‍α and IL-6), which give positive feedback through the NF-‍κB pathway, thereby amplifying the initial inflammatory signal. The activation of NF-‍κB is influenced by many regulators that act on adaptor proteins and kinases of the NF-‍κB pathway. The E3 ligase TRIM23 regulates the activation of NEMO by atypical K27-linked poly-ubiquitination, and the linear ubiquitin chain assembly complex (LUBAC), another E3 ligase, catalyzes the linear ubiquitination of NEMO at K285 and K309 (Zheng and Gao, 2020). The viral FLICE-like inhibitory protein (FLIP) forms a stable complex with a central region of the inhibitor of IKK-γ and activates the NF-‍κB pathway via IKK activation (Baratchianet al., 2016).

4 Negative regulation of TLR3 signaling

The PRR pathways are controlled by many external and intracellular molecules to maintain a balance between activation and inhibition, thus balancing the beneficial and adverse effects of antigen detection (Antosz and Choroszyńska, 2013). The mechanism of negative regulation with TLR is most developed in immune cells. It is strictly limited to a specific TLR and operates at multiple levels of TLR signaling. Here, we focus on TLR3-negative regulators, which inhibit signals at different stages of activation (Fig. 3).

Fig. 3. Negative regulation of TLR3 signaling. The trunk of the TLR3-TRIF signaling pathway is shown in purple; ubiquitination modifying enzymes that negatively regulate the pathway are in blue; other negative regulators, such as membrane proteins, adaptor proteins, and phosphatases, are in pink. AP-1: activator protein 1; c-Cbl: Casitas B-lineage lymphoma; DTX4: Deltex 4; DUBA: deubiquitinating enzyme A; DUSP14: dual-specificity phosphatase 14; IκB: inhibitor of κB; IKK: IκB kinase-related kinase; IKIP: IKK-interacting protein; IRF3: interferon (IFN)-regulatory factor 3; MAPK: mitogen-activated protein kinase; MKRN2: makorin ring finger protein 2; NF-‍κB: nuclear transcription factor-‍κB; NEMO: NF-κB essential modifier; PDLIM2: PDZ and LIM domain-containing protein 2; PSMB: proteasome β subunit; RAUL: transcriptional activator (RTA)‍-associated ubiquitin ligase; RBCK1: RBCC protein interacting with PKC1; RIP-1: receptor-interacting protein-1; RNF: ring finger protein; SARM: sterile α and HEAT/Armadillo motif; SHP: small heterodimer partner; SOCS: suppressor of cytokine signaling; TGF-‍β: transforming growth factor-‍β; TAK1: TGF-‍β-activated kinase 1; TLR3: Toll-like receptor 3; TNF: tumor necrosis factor; TRAF: TNF receptor-associated factor; TBK1: TRAF family member-associated NF-κB activator (TANK)‍-binding kinase 1; TRAIL: TNF-related apoptosis-inducing ligand; TRIF: Toll-interleukin-1 receptor (TIR)‍-domain-containing adaptor-inducing IFN-‍β; TRIM: tripartite motif-containing protein; TRIP: TRAF-interacting protein; USP2a: ubiquitin-specific protease 2 isoform a; USP19: ubiquitin-specific protease 19; WWP2: WW domain-containing protein 2.

Fig. 3

Open in a new tab

4.1. Negative regulation of ubiquitination modifying enzymes

E3 ubiquitin ligases and deubiquitinases (DUBs), as the master regulators of TLR signaling, cooperatively regulate the dynamic and reversible ubiquitination process (Zheng and Gao, 2020).

The TLR3-binding E3 ligase RNF170 mediates the K48-linked poly-ubiquitination of K766 in the TIR domain of TLR3 (Songet al., 2020). RNF170 promotes the degradation of TLR3 via the proteasome pathway, thus selectively inhibiting TLR3-mediated pathways (Song et al., 2020). TRIM38 associates with the N-terminus of TRIF through its PRYSPRY domain to mediate K48-linked poly-ubiquitination and degradation of TRIF. Other proteins involved in this process are WW domain-containing protein 2 (WWP2) and Casitas B-lineage lymphoma (c-Cbl) (Han et al., 2010; Xueet al., 2012; Yanget al., 2013).

The E3 ubiquitin ligases TRAF-interacting protein (TRIP), Deltex4 (DTX4), TRIM27, and TRIM8 are responsible for modulating the turnover of TBK1 through K48-linked poly-ubiquitination (Cuiet al., 2012; Zhanget al., 2012; Zhenget al., 2015; Yeet al., 2017). The E3 ligases RBCC protein interacting with PKC1 (RBCK1), c-Cbl, TRIM26, and RNA transcriptional activator (RTA)‍-associated ubiquitin ligase (RAUL) target the nuclear IRF3 for K48-linked poly-ubiquitination and degradation (Yu and Hayward, 2010; Wanget al., 2015; ZhaoXB et al., 2016).

E3 ligase ubiquitin-specific protease 19 (USP19) induces deconjugation of K63- and K27-linked polyubiquitin chains from TAK1, resulting in disruption of the TAK1-TAB2/3 complex (Leiet al., 2019). Additionally, USP19 impairs the recruitment of TRIF to TLR3/4 by catalyzing the removal of TRIF K27-linked polyubiquitin moieties (Wu X et al., 2019). TRIM29 and TRAF7 promote the turnover of NEMO by facilitating the K48- and K29-linked poly-ubiquitination of NEMO, respectively (Xinget al., 2016). Makorin ring finger protein 2 (MKRN2) and PDZ and LIM domain-containing protein 2 (PDLIM2) cooperatively promote the K48-linked poly-ubiquitination and proteasomal degradation of nuclear p65 (Shinet al., 2017). RNF182 can also contribute to the degradation of p65 via K48-linked ubiquitination, thus inhibiting TLR3-triggered proinflammatory responses (Cao Yet al., 2019).

DUBs, such as A20, deubiquitinating enzyme A (DUBA), and USP2, are reported to be involved in the type I IFN pathway. Zinc-finger protein A20 is a negative regulator that regulates both MyD88- and TRIF-dependent TLR signaling pathways (Saitohet al., 2005). Saitoh et al. (2005) reported that A20 negatively regulates TLR3-mediated IFN-β gene transcription by inhibiting IRF3 activation. A20 also prevents NF-‍κB activation via the A20‍–‍TRAF6 axis (Booneet al., 2004). DUBA negatively regulates TLR3-mediated type I IFN production by selectively cleaving the Lys63-linked polyubiquitin chains on TRAF3 (Kayagakiet al., 2007). USP2a negatively regulates NF-‍κB activation by cleaving K63-linked polyubiquitin chains on TRAF6 (Heet al., 2013). USP2b targets TBK1 and deubiquitinates TBK1 K63-linked poly-ubiquitination, thus negatively modulating the TLR3/4 signaling pathway (Zhanget al., 2014).

The members of the suppressor of cytokine signaling (SOCS) family also participate in immune response regulation (Antosz and Choroszyńska, 2013). SOCS1 targets the subunit p65 (RelA)‍-NF-‍κB and leads to proteolysis of the NF-κB molecule by ubiquitination (Ryoet al., 2003). SOCS3 represses TRAF6 activation to block the subsequent activation of TAK1, which must activate both the NF-‍κB and MAPK pathways (Frobøseet al., 2006).

4.2. Negative regulation of membrane proteins

The TNF-related apoptosis-inducing ligand (TRAIL) cytokine was identified as a member of the TNF superfamily which initiates the apoptotic pathway in many cancer cell lines (Yuanet al., 2018). Diehl et al. (2004) claimed that TRAIL-R inhibits TLR signaling by stabilizing IkBα and decreasing the expression of the transcription factor NF-‍κB, and showed that TLR2, TLR3, and TLR4 ligands bolster the expression of TRAIL-R. In contrast, in the case of TRAIL-R deficit, there is an increased production of cytokines in response to these ligands (Diehl et al., 2004).

4.3. Negative regulation of adaptor proteins

β-Arrestin 1 and β-arrestin 2 are ubiquitously expressed multifunctional scaffolding proteins that affect inflammatory signaling in various cell lines (Freedman and Shenoy, 2018). β-Arrestins participate in intracellular signaling by playing a role as MAPK scaffolds or mediating Src activation (Laporte and Scott, 2019). Witherow et al. (2004) indicated that β‍-arrestin is involved in modulating TLR signaling by affecting NF-‍κB activation. Research by Wang et al. (2006) showed that β‍-arrestin interacts with TRAF6 via the TIR domain, thus preventing the auto-ubiquitination and oligomerization of TRAF6 required for the activation of NF-κB and AP-1.

Sterile α and HEAT/Armadillo motif (SARM), the most conserved member of the TIR adaptor family, is located in the cytoplasm and directly affects the cytosol TRIF, decreasing NF-‍κB and IRF3, and thus negatively regulates TRIF-dependent signaling induced by TLR3 and TLR4 (Carty and Bowie, 2019). Research by Penget al. (2010) showed that, in human cells, SARM blocks the TRIF- and MyD88-dependent activation of AP-1 and the endogenous form of AP-1.

4.4. Negative regulation of phosphatases

Small heterodimer partner (SHP) is also a negative TLR signaling regulator (Zhang and Shen, 2011). In resting cells, SHP inhibits NF-κB-dependent signaling by interacting with p65-NF-κB (Zhang and Shen, 2011). Upon stimulation, SHP decreases the TRAF6 Lys63-link polyubiquitin by interacting with the RING TRAF6 domain (Yuket al., 2011). DUSP14, a member of the dual-specificity phosphatase (DUSP) family, represses TNF- and IL-1β-triggered NF-κB activation by dephosphorylating TAK1 T187 (Zheng et al., 2013).

4.5. Other negative regulators

PSMB1 is a proteasome β subunit (PSMB) family member, which inhibits the TLR and RLR signaling pathways (Sorokinet al., 2009; Wu FYet al., 2019). The silencing of PSMB1 increases IFN-β production, whereas overexpression of PSMB1 inhibits activation of virus-induced IFN-β promoter (Wu FY et al., 2019). PSMB1 promotes the degradation of IKK-ε by interacting with IKK-‍ε through the ubiquitin-proteasome system (Wu FY et al., 2019). IKK-interacting protein (IKIP) inhibits the formation of IKK complex by binding to IKK-α/β in competition with NEMO, thus hindering the phosphorylation of IKK-α/β and negatively regulating the activation of the downstream NF-‍‍κB signaling pathway (Wu HFet al., 2020). In the presence of lipopolysaccharide (LPS), poly(I:C), TNF-‍α, and IL-1β stimulation, the phosphorylation of IKK-‍α/β, IκB, and p65 is enhanced, and the expression of TNF-α and IL-6 is increased in the macrophages of IKIP-deficient mice (Wu HF et al., 2020).

The signals transmitted from TLR are controlled by specific inhibitors, which show tissue and cellular specificity in many cases. However, the mechanisms underlying this specificity are poorly understood. Many inhibitory factors known to affect TLR signaling have yet to be evaluated.

5 Antiviral effects of TLR3

TLR3 may be a double-edged sword that functions in ensuring or compromising host immunity against viruses (Perales-Linares and Navas-Martin, 2013) (Table 1). TLR3-mediated signaling during viral infections protects against correlative diseases by reducing the viral loads and modulating immune responses, while over-activation of the pathogenic immune response induced by TLR3 signal transduction can lead to pathogenesis (Perales-Linares and Navas-Martin, 2013). Thus, the tight balance between a controlled antiviral response and excessive immune activation determines the pathological outcome of TLR3-related diseases. The TLR3 pathway can control immunity to most of the clinically relevant viral infections in humans, including those caused by flaviviruses, hepatitis viruses, RV, herpesvirus, retroviruses, encephalomyocarditis virus, orthomyxoviruses, and the currently epidemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Table 1.

Roles of TLR3 in antiviral responses

Effect Virus Target organ Disease Role of TLR3
Protection Herpes simplex virus type 1 (HSV-1) Central nervous system (CNS) Encephalitis or others TLR3 recruits the metabolic checkpoint kinase complex mTORC2, thus enabling the activation of molecules (including mTORC1) required for type I IFN induction (Mielcarska et al., 2018).
Encephalomyocarditis virus (EMCV) Myocardium, brain Encephalomyocarditis TLR3 decreases viral replication in the heart, and decreases myocardial injury (Hardarson et al., 2007).
Coxsackievirus strain B serotype 3 (CVB3) Myocardium, meninges, pancreas Acute and chronic myocarditis, meningitis, and pancreatitis TLR3 resists CVB3 infection and prevents the progression from myocarditis to iDCM (Abston et al. (2013); Sesti-Costa et al ., 2017).
Murine cytomegalovirus (MCMV) Liver Hepatitis Cytokine (type Ⅰ IFN, IFN-γ, and IL-12p40) production, and NK cell and NKT cell activation are impaired in TLR3-deficient mice compared with wild-type mice (Matsumoto et al., 2011).
Rotavirus (RV) Kidney Glomerulonephritis TLR3 plays a synergistic role with protective factors and down-regulates the expression of cytokines induced by RV (Jiang et al., 2017).
Poliovirus (PV) Bone marrow Poliomyelitis TLR3-TRIF signaling pathway governs IFN induction and host protection against PV infection (Oshiumi et al ., 2011).
Human immunodeficiency virus 1 (HIV-1) CD4+ and CD8+ T cells, macrophages, others Immunodeficiency,encephalitis, and others TLR3 decreases HIV-1 infection in macrophages and enhances the development of HIV-specific CD4+ and CD8 + cytotoxic T lymphocytes (Cheng et al., 2018; Nguyen et al., 2020).
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Respiratory tract Coronavirus disease 2019 (COVID-19) TLR3- and IRF7-dependent type I IFN immunity may be essential for preventing life-threatening COVID-19 pneumonia (Zhang et al., 2020).
Influenza A virus (IAV) CNS, brain Encephalopathy TLR3 signaling pathways are activated preferentially following IAV infection to release a range of proinflammatory cytokines (Huo et al., 2018).
Deterioration Phlebovirus Liver Hepatopathy Compared with TLR3-deficient mice, wild-type mice demonstrate decreased resistance to lethal infection. The result may be caused by overproduction of inflammatory mediators via TLR3 signaling (Gowen et al., 2006).
Bi-direction Hepatitis C virus (HCV) Liver Hepatitis C

Protection: TLR3 inhibits HCV replication in Huh7 cells (Zhou et al., 2016).

Deterioration: TLR3 possibly contributes to the intrahepatic and unbalanced proinflammatory response (Li et al., 2012).
Hepatitis B virus (HBV) Liver Hepatitis

Protection: TLR3-knockout mice are unable to express IL-8 and other requisite molecules to activate immune responses against HBV (Maire et al., 2008). Activation of mDC using TLR3 ligands leads to improved NK cell function in CHB infection (Tjwa et al., 2012).

Deterioration: TLR3 polymorphism rs3775291 was associated with an increased risk of developing CHB (Geng et al., 2016; Fischer et al., 2018).
West Nile virus (WNV) Brain Encephalitis

Protection: TLR3 restricts WNV replication in neurons and antagonizes against NS1 (Daffis et al., 2008; Wilson et al., 2008).

Deterioration: compared with TLR3-deficient mice, wild-type mice are less resistant to lethal WNV infection (Wang et al., 2004). Increased frequency of WNV encephalitis in elderly humans may be related to increased TLR3 signaling (Kong et al ., 2008).
Unclear Influenza A (H1N1) Lung Pneumonia The presence of TLR3 rs5743313/CT polymorphism has a close relationship with the increased risk of pneumonia in children infected by the pandemic A/H1N1/2009 (Esposito et al., 2012). TLR3 does not worsen the pathogenesis of pH1N1 infection (Leung et al., 2014).
Tick-borne encephalitis virus (TBEV) CNS Encephalitis TLR3 may be a risk factor for TBEV infection (Kindberg et al., 2011).
Open in a new tab

CD: cluster of differentiation; CHB: chronic hepatitis B; iDCM: inflammatory dilated cardiomyopathy; IFN: interferon; IL: interleukin; IRF: IFN-regulatory factor; mDC: myeloid dendritic cell; mTORC: mammalian target of rapamycin complex; NK: natural killer; NKT: natural killer T; NS1: non-structural protein 1; pH1N1: pandemic H1N1 influenza; TLR3: Toll-like receptor 3; TRIF: Toll-IL-1 receptor (TIR)-domain-containing adaptor-inducing IFN-β.

An essential role for TLR3 in protection from herpes simplex virus type 1 (HSV-1) infection has been demonstrated (Zhang et al., 2007). HSV-1 is a prevalent neurotropic virus that infects the central nervous system (CNS) and generates herpes simplex encephalitis (HSE) in children with inborn errors of TLR3 immunity (Sancho-Shimizu et al., 2011). The pathogenesis of HSE in children with TLR3-pathway deficiencies is related to impaired TLR3- and Unc-93 homolog B (UNC-93B)‍-dependent IFN-‍α/β intrinsic immunity against HSV-1 in the CNS (Lafaille et al., 2012). Sato et al. (2018) demonstrated that TLR3 was required for innate immune responses to HSV-1 in neurons and astrocytes. Upon HSV-1 infection, TLR3 recruited the metabolic checkpoint kinase complex mammalian target of rapamycin complex 2 (mTORC2), which led to chemokine induction and TLR3 trafficking to the cell periphery, thus enabling the activation of molecules (including mTORC1) required for type I IFN induction (Mielcarska et al., 2018). In contrast, the failure to express a functional TLR3 disrupted signaling mechanisms that induced antiviral response during infection with HSV-1, indicating that TLR3 is essential for effective antiviral immunity in HSV infection (Mielcarska et al., 2018).

Coxsackievirus strain B serotype 3 (CVB3) is a positive-sense ssRNA virus of the Picornaviridae family (Esfandiarei and McManus, 2008). CVB3 is one of the main causes of myocarditis, and causes a wide range of other infections such as meningitis and pancreatitis (Corsten et al., 2012). It has been reported that TLR3-deficient mice are more susceptible to acute CVB3-induced myocarditis, which is externalized as increased viral load and myocardial tissue damage (Negishi et al., 2008). Abston et al. (2013) revealed that TLR3 prevented the progression from myocarditis to inflammatory dilated cardiomyopathy (iDCM) following CVB3 infection by reducing the IL-4 level and acute viral replication in the heart. Sesti-Costa et al. (2017) found that TLR3 up-regulated CD80 and CD86 in DCs to resist CVB3 infection. In the absence of TLR3, DCs secreted higher levels of the inhibitory molecule programmed death-ligand 1 (PD-L1), while lowering the levels of TNF-‍α and IL-10 (Sesti-Costa et al., 2017).

The up-regulation of epithelial TLR3 expression during infancy might contribute to age-dependent susceptibility to RV infection (Pottet al., 2012). Jiang et al. (2017) demonstrated that probiotics acted on the TLR3/NF-κB signaling pathway during treatment for diarrhea caused by RV. This not only played a synergistic role with protective factors, but also down-regulated the expression of cytokines induced by RV, thus protecting small intestinal epithelial cells and repairing small intestinal injury. Sanderet al. (2017) found that prostaglandin E2 (PGE2) directly induced autoimmunity in RV infection and triggered TLR signals, thereby inhibiting viral binding and stimulating viral gene expression.

Based on existing data, it is postulated that TLR3 may contribute to the progression toward the acquired immune deficiency syndrome (AIDS). Myeloid DCs are the primary targets of human immunodeficiency virus 1 (HIV-1) lentiviral transduction following subcutaneous immunization (Martin-Gayo and Yu, 2017). The lentiviral activation of DCs depends on TLR3/7 (Breckpotet al., 2010). Bhargavan et al. (2016) demonstrated that TLR3 activation increased HIV-1 transactivation via the NF-‍κB and JNK pathways. Other evidence suggests that selective TLR3 activation promotes the production of type I IFNs, β‍-chemokines, and miRNA-155, which preferentially target the 3' untranslated region (UTR) of HIV-1 transcript. This significantly decreases HIV-1 infection in macrophages and enhances the development of HIV-specific CD4+ and CD8+ cytotoxic T lymphocytes in humanized mice (Cheng et al., 2018; Nguyen et al., 2020). The gene expression of TLR3 is markedly increased in advanced HIV-1-infected human macrophages, but shows no significant difference in chronic HIV-1-infected and healthy ones (Alvarez-Carbonell et al., 2017; Liu and Gack, 2020). In addition, triggering TLR3 with specific ligands could have therapeutic potential against HIV-1 infection in humans. A combined TLR3 agonist and CD40-targeting HIV-1 vaccine therapy is being established against HIV-1 disease (Cheng et al., 2018; Saxena et al., 2019). The HIV5pep with poly(I:C) vaccination approach was demonstrated to activate the replication of HIV-1 reservoirs and enhance the anti-HIV-1 T-cell response, resulting in reduced HIV-1 pools (Cheng et al., 2018).

Studies have shown that TLR3 is closely related to the current pandemic of coronavirus disease 2019 (COVID-19) caused by a novel virus strain, 2019 novel coronavirus (2019-nCoV)/SARS-CoV-2. SARS-CoV-2 is a positive-sense, ssRNA, β-coronavirus of the Coronaviridae family, which disrupts the host innate immune response and causes fatal acute respiratory distress syndrome (ARDS) (Guanet al., 2020; Wu Fet al., 2020). An enrichment in rare variants predicted to be loss-of-function (LOF) at the 13 human loci known to govern TLR3- and IRF7-dependent type I IFN immunity to influenza virus has been found in patients with lethal COVID-19 relative to those with asymptomatic or benign infection (Zhang et al., 2020). Therefore, TLR3- and IRF7-dependent type I IFN immunity may be essential for preventing life-threatening COVID-19 pneumonia. Furthermore, TLR3 agonists, like chloroquine, can be considered potential drugs for repurposing in COVID-19 treatment (Gao et al., 2020; Prasad et al., 2020). TLR3 is also a critical antigenic receptor for binding newly designed multi-epitope vaccines for COVID-19 (Dong et al., 2020; Ismail et al., 2020).

Hidaka et al. (2006) found a missense mutation (F3035) in the TLR3 gene related to encephalopathy caused by the influenza A virus (IAV). Meng et al. (2016) reported that after IAV infection, mouse mastocytoma cell line (P815) cells mediate hyper-induction of proinflammatory cytokines and chemokines, with TLR3 playing a key role in the expression of proinflammatory cytokines. Huo et al. (2018) showed that, compared with other virus infections and inflammation, the TLR3 signaling pathways are activated preferentially following IAV infection to release a range of proinflammatory cytokines.

Evidence suggests that TLR3 shows both protective and damaging functions in the context of some human viral infections. Hepatitis C virus (HCV), a ssRNA virus, induces hepatitis C, probably along with developing complications such as cirrhosis, liver failure, and hepatocellular carcinoma (Spearman et al., 2019). Li et al. (2012) reported that TLR3 may contribute to the intrahepatic and unbalanced proinflammatory response. In contrast, a recent report showed that TLR3 activates macrophages to release exosomes that contain anti-HCV microRNA-29 (miR-29) family members, thereby inhibiting HCV replication in Huh7 cells (Zhou et al., 2016). Mosaad et al. (2019) further proved that the heterozygous CT genotype of TLR3 rs3775290 might be a susceptibility risk factor for chronic HCV infection. In contrast, the combination of female CC-AT-GA and the homozygous CC genotypes may be protective.

Hepatitis B virus (HBV) is a prevalent infectious agent which causes impaired liver function in humans (Assaret al., 2012). The role of TLR3 in HBV infection is also bi-directional. It has been reported that TLR3-knockout mice are unable to express IL-8 and other requisite molecules to activate immune responses against HBV (Maireet al., 2008). An et al. (2007) found that patients with chronic HBV infection presented a slower elevation of TLR3 expression than healthy controls. Ondondo et al. (2009) revealed that patients with chronic hepatitis B (CHB) expressed lower TLR3 in monocyte-derived DCs (MoDCs) than normal controls. Based on the above two research findings, impairment of TLR3 expression and function was thought to be a major reason for the persistence of HBV infection (Karimi-Googheri and Arababadi, 2014). Additionally, Tjwa et al. (2012) demonstrated that activation of myeloid DC using TLR3 ligands led to improved natural killer (NK) cell function in CHB infection. Wang Ket al. (2010) found that messenger RNA (mRNA) levels of TLR3 increased in CHB in the active phase, suggesting that TLR3 may play a vital role in starting innate immunity. Nevertheless, recent reports showed that the TLR3 polymorphism rs3775291 was associated with reduced spontaneous hepatitis B surface antigen (HBsAg) seroclearance (SC) of HBV infection and an increased risk of developing CHB (Geng et al., 2016; Fischer et al., 2018).

WNV is a flavivirus transmitted by mosquitoes, which causes encephalitis, especially in the elderly and immunocompromised individuals (Kramer et al., 2008). WNV non-structural protein 1 (NS1) is a crucial gene required for viral RNA replication and inhibiting TLR3-mediated signal transduction (Wilson et al., 2008). However, data on the role of TLR3 signaling in WNV protection or pathogenesis are controversial. While some studies have suggested that TLR3 serves a protective role against WNV by restricting WNV replication in neurons and through its antagonism against NS1 (Daffis et al., 2008; Wilson et al., 2008), others have demonstrated that compared with TLR3-deficient mice, the WT mice were less resistant to lethal WNV infection (Wang et al., 2004). Kong et al. (2008) found that during WNV infection, the expression of TLR3 was reduced in macrophages of young donors, but increased in those of the elderly. This change with aging suggested that increased incidence of WNV encephalitis in elderly humans may be linked to increased TLR3 signaling, which may lead to elevated cytokine levels and contribute to the permeability of the blood-brain barrier. Recent research showed that immunization with NS1 might reduce brain inflammation in the context of TLR3 deficiency (Patel et al., 2019).

The presence of the TLR3 rs5743313/CT polymorphism is closely related to an increased risk of pneumonia in children infected by the pandemic A/influenza A (H1N1)/2009 influenza virus (Esposito et al., 2012). A recent study showed that A/HK/415742/09 (pandemic H1N1 influenza (pH1N1)) virus-infected TLR3-/- mice did not have better survival than pH1N1-infected WT mice and showed no difference in viral titer and leukocyte infiltration in the lungs, suggesting that TLR3 did not worsen the pathogenesis of pH1N1 infection (Leung et al., 2014). The precise role of TLR3 against influenza in humans remains to be determined.

The effect of TLR3 on susceptibility to tick-borne encephalitis virus (TBEV) infection is poorly understood. Research by Kindberg et al. (2011) showed that the WT rs3775291 TLR3 allele was more common among TBEV patients than in healthy controls, suggesting that TLR3 might be a risk factor for TBEV infection. It was recently reported that polymorphisms in TLR3 have a statistically significant impact on TBEV infection (Mickienė et al., 2014).

6 Conclusions and future directions

In this review, we discussed the TLR3-mediated antiviral response based on the activation and regulation of the TRIF signaling pathway. The TRIF and TRIF-mediated signaling pathways are critical for understanding the role of TLR3 in the immune response, which could give us a new direction to clarify the pathogenesis of diseases and find cures. Significant progress has been made in dissecting the mechanisms of TRIF-dependent activation of IRF3 and NF-‍κB, but how the TRIF/AP-1 pathway works needs further study. Recent work has focused on proteins that act as adaptors or mediate the activation of adaptors on the TRIF pathway, but some of their mechanisms remain to be further determined. A variety of enzymes that act as negative regulatory agencies of TLR3 have been found, but how these regulators are activated during viral infection and their cell type- and species-specific roles remain unclear.

Moreover, the dual role of TLR3 in ensuring or compromising host immunity against viruses is still largely unknown. In the case of chronic RNA viral infections that lead to sustained IFN-‍α/β signaling, the TLR3-TRIF axis may be crucial in determining how the balance between antiviral and immune regulatory pathways affects defensive versus offensive responses. In future work, the TLR3-TRIF pathway may be essential for the establishment of specific therapeutic approaches to diminish TLR3-driven disease.

Acknowledgments

This work was supported by the National Key R&D Program of China (No. ‍2018YFD0501705), the Chongqing Basic Research Program (No.‍ cstc2018jcyjAX0615), and the Fundamental Research Funds for the Central Universities (Nos. XDJK2018C059 and XDJK2018C060), China. We thank LetPub (http://www.letpub.com) for its linguistic assistance and scientific consultation during the preparation of this manuscript.

AUTHORS’CONTRIBUTIONS

Huashan YI, Yujuan CHEN, and Xianping MA were responsible for conceptualization; Yujuan CHEN, Junhong LIN, and Yao ZHAO for article writing, data collection, and manuscript revision; Yujuan CHEN for picture design; and Xianping MA and Huashan YI for supervision. All authors have read and approved the final manuscript.

Compliance with ethics guidelines

Yujuan CHEN, Junhong LIN, Yao ZHAO, Xianping MA, and Huashan YI declare that they have no conflict of interest.

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

  1. Abston ED, Coronado MJ, Bucek A, et al. , 2013. TLR3 deficiency induces chronic inflammatory cardiomyopathy in resistant mice following coxsackievirus B3 infection: role for IL-4. Am J Phys Regul Integr Comp Phys, 304(4): R267-R277. 10.1152/ajpregu.00516.2011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Agier J, Żelechowska P, Kozłowska E, et al. , 2016. Expression of surface and intracellular Toll-like receptors by mature mast cells. Cent Eur J Immunol, 41(4): 333-338. 10.5114/ceji.2016.65131 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Alexopoulou L, Holt AC, Medzhitov R, et al. , 2001. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature, 413(6857): 732-738. 10.1038/35099560 [DOI] [PubMed] [Google Scholar]
  4. Alvarez-Carbonell D, Garcia-Mesa Y, Milne S, et al. , 2017. Toll-like receptor 3 activation selectively reverses HIV latency in microglial cells. Retrovirology, 14: 9. 10.1186/s12977-017-0335-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Ameyar M, Wisniewska M, Weitzman JB, 2003. A role for AP-1 in apoptosis: the case for and against. Biochimie, 85(8): 747-752. 10.1016/j.biochi.2003.09.006 [DOI] [PubMed] [Google Scholar]
  6. An BY, Xie Q, Lin LY, et al. , 2007. Expression of Toll-like receptor 3 on peripheral blood dendritic cells in HBeAg positive patients with chronic hepatitis B. Chin J Hepatol, 15(10): 729-733(in Chinese). 10.3760/j.issn:1007-3418.2007.10.003 [DOI] [PubMed] [Google Scholar]
  7. Antosz H, Choroszyńska D, 2013. Negative regulation of Toll-like receptor signalling. Postepy Hig Med Dosw, 67: 339-350. 10.5604/17322693.1046538 [DOI] [PubMed] [Google Scholar]
  8. Assar S, Arababadi MK, Ahmadabadi BN, et al. , 2012. Occult hepatitis B virus (HBV) infection: a global challenge for medicine. Clin Lab, 58(11-12): 1225-1230. [PubMed] [Google Scholar]
  9. Baratchian M, Davis CA, Shimizu A, et al. , 2016. Distinct activation mechanisms of NF-‍κB regulator inhibitor of NF-κB kinase (IKK) by isoforms of the cell death regulator cellular FLICE-like inhibitory protein (cFLIP). J Biol Chem, 291(14): 7608-7620. 10.1074/jbc.M116.718122 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Barton GM, Kagan JC, 2009. A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol, 9(8): 535-542. 10.1038/nri2587 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Bhargavan B, Woollard SM, Kanmogne GD, 2016. Toll-like receptor-3 mediates HIV-1 transactivation via NFκB and JNK pathways and histone acetylation, but prolonged activation suppresses Tat and HIV-1 replication. Cell Signal, 28(2): 7-22. 10.1016/j.cellsig.2015.11.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Blasius AL, Beutler B, 2010. Intracellular Toll-like receptors. Immunity, 32(3): 305-315. 10.1016/j.immuni.2010.03.012 [DOI] [PubMed] [Google Scholar]
  13. Boone DL, Turer EE, Lee EG, et al. , 2004. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol, 5(10): ‍1052-1060. 10.1038/ni1110 [DOI] [PubMed] [Google Scholar]
  14. Botos I, Liu L, Wang Y, et al. , 2009. The Toll-like receptor 3: dsRNA signaling complex. Biochim Biophys Acta Gene Regul Mech, 1789(9-10): 667-674. 10.1016/j.bbagrm.2009.06.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Breckpot K, Escors D, Arce F, et al. , 2010. HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. J Virol, 84(11): 5627-5636. 10.1128/jvi.00014-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Bugge M, Bergstrom B, Eide OK, et al. , 2017. Surface Toll-like receptor 3 expression in metastatic intestinal epithelial cells induces inflammatory cytokine production and promotes invasiveness. J Biol Chem, 292(37): ‍15408-15425. 10.1074/jbc.M117.784090 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Cao LL, Liu SD, Li YF, et al. , 2019. The nuclear matrix protein SAFA surveils viral RNA and facilitates immunity by activating antiviral enhancers and super-enhancers. Cell Host Microbe, 26(3): 369-384.e8. 10.1016/j.chom.2019.08.010 [DOI] [PubMed] [Google Scholar]
  18. Cao Y, Sun Y, Chang HY, et al. , 2019. The E3 ubiquitin ligase RNF182 inhibits TLR-triggered cytokine production through promoting p65 ubiquitination and degradation. FEBS Lett, 593(22): 3210-3219. 10.1002/1873-3468.13583 [DOI] [PubMed] [Google Scholar]
  19. Cartwright T, Perkins ND, Wilson CL, 2016. NFKB1: a suppressor of inflammation, ageing and cancer. FEBS J, 283(10): 1812-1822. 10.1111/febs.13627 [DOI] [PubMed] [Google Scholar]
  20. Carty M, Bowie AG, 2019. SARM: from immune regulator to cell executioner. Biochem Pharmacol, 161: 52-62. 10.1016/j.bcp.2019.01.005 [DOI] [PubMed] [Google Scholar]
  21. Chen CY, Shih YC, Hung YF, et al. , 2019. Beyond defense: regulation of neuronal morphogenesis and brain functions via Toll-like receptors. J Biomed Sci, 26: 90. 10.1186/s12929-019-0584-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Chen HW, Yang YK, Xu H, et al. , 2015. Ring finger protein 166 potentiates RNA virus-induced interferon-β production via enhancing the ubiquitination of TRAF3 and TRAF6. Sci Rep, 5: 14770. 10.1038/srep14770 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Cheng L, Wang Q, Li GM, et al. , 2018. TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs. J Clin Invest, 128(10): 4387-4396. 10.1172/jci99005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Choe J, Kelker MS, Wilson IA, 2005. Crystal structure of human Toll-like receptor 3 (TLR3) ectodomain. Science, 309(5734): 581-585. 10.1126/science.1115253 [DOI] [PubMed] [Google Scholar]
  25. Corcoran SE, O'Neill LAJ, 2016. HIF1α and metabolic reprogramming in inflammation. J Clin Invest, 126(10): 3699-3707. 10.1172/jci84431 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Corsten MF, Schroen B, Heymans S, 2012. Inflammation in viral myocarditis: friend or foe? Trends Mol Med, 18(7): 426-437. 10.1016/j.molmed.2012.05.005 [DOI] [PubMed] [Google Scholar]
  27. Cui J, Li YY, Zhu L, et al. , 2012. NLRP4 negatively regulates type I interferon signaling by targeting the kinase TBK1 for degradation via the ubiquitin ligase DTX4. Nat Immunol, 13(4): 387-395. 10.1038/ni.2239 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Daffis S, Samuel MA, Suthar MS, et al. , 2008. Toll-like receptor 3 has a protective role against West Nile virus infection. J Virol, 82(21): 10349-10358. 10.1128/jvi.00935-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Diehl GE, Yue HH, Hsieh K, et al. , 2004. TRAIL-R as a negative regulator of innate immune cell responses. Immunity, 21(6): 877-889. 10.1016/j.immuni.2004.11.008 [DOI] [PubMed] [Google Scholar]
  30. Dong R, Chu ZG, Yu FX, et al. , 2020. Contriving multi-epitope subunit of vaccine for COVID-19: immunoinformatics approaches. Front Immunol, 11: 1784. 10.3389/fimmu.2020.01784 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Doyle M, Jantsch MF, 2002. New and old roles of the double-stranded RNA-binding domain. J Struct Biol, 140(1-3): 147-153. 10.1016/s1047-8477(02)00544-0 [DOI] [PubMed] [Google Scholar]
  32. Emmerich CH, Ordureau A, Strickson S, et al. , 2013. Activation of the canonical IKK complex by K63/M1-linked hybrid ubiquitin chains. Proc Natl Acad Sci USA, 110(38): 15247-15252. 10.1073/pnas.1314715110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Ermolaeva MA, Michallet MC, Papadopoulou N, et al. , 2008. Function of TRADD in tumor necrosis factor receptor 1 signaling and in TRIF-dependent inflammatory responses. Nat Immunol, 9(9): 1037-1046. 10.1038/ni.1638 [DOI] [PubMed] [Google Scholar]
  34. Esfandiarei M, McManus BM, 2008. Molecular biology and pathogenesis of viral myocarditis. Annu Rev Pathol Mech Dis, 3: 127-155. 10.1146/annurev.pathmechdis.3.121806.151534 [DOI] [PubMed] [Google Scholar]
  35. Esposito S, Molteni CG, Giliani S, et al. , 2012. Toll-like receptor 3 gene polymorphisms and severity of pandemic A/H1N1/2009 influenza in otherwise healthy children. Virol J, 9: 270. 10.1186/1743-422x-9-270 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Ewald SE, Engel A, Lee J, et al. , 2011. Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase. J Exp Med, 208(4): 643-651. 10.1084/jem.20100682 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Fang F, Ooka K, Sun XY, et al. , 2013. A synthetic TLR3 ligand mitigates profibrotic fibroblast responses by inducing autocrine IFN signaling. J Immunol, 191(6): 2956-2966. 10.4049/jimmunol.1300376 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Fischer J, Koukoulioti E, Schott E, et al. , 2018. Polymorphisms in the Toll-like receptor 3 (TLR3) gene are associated with the natural course of hepatitis B virus infection in caucasian population. Sci Rep, 8: 12737. 10.1038/s41598-018-31065-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Fitzgerald KA, Kagan JC, 2020. Toll-like receptors and the control of immunity. Cell, 180(6): 1044-1066. 10.1016/j.cell.2020.02.041 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Freedman NJ, Shenoy SK, 2018. Regulation of inflammation by β-arrestins: not just receptor tales. Cell Signal, 41: 41-45. 10.1016/j.cellsig.2017.02.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Frobøse H, Rønn SG, Heding PE, et al. , 2006. Suppressor of cytokine signaling-3 inhibits interleukin-1 signaling by targeting the TRAF-6/TAK1 complex. Mol Endocrinol, 20(7): 1587-1596. 10.1210/me.2005-0301 [DOI] [PubMed] [Google Scholar]
  42. Funami K, Matsumoto M, Oshiumi H, et al. , 2004. The cytoplasmic ‘linker region’ in Toll-like receptor 3 controls receptor localization and signaling. Int Immunol, 16(8): 1143-1154. 10.1093/intimm/dxh115 [DOI] [PubMed] [Google Scholar]
  43. Funami K, Sasai M, Ohba Y, et al. , 2007. Spatiotemporal mobilization of Toll/IL-1 receptor domain-containing adaptor molecule-1 in response to dsRNA. J Immunol, 179(10): 6867-6872. 10.4049/jimmunol.179.10.6867 [DOI] [PubMed] [Google Scholar]
  44. Funami K, Sasai M, Oshiumi H, et al. , 2008. Homo-oligomerization is essential for Toll/interleukin-1 receptor domain-containing adaptor molecule-1-mediated NF-κB and interferon regulatory factor-3 activation. J Biol Chem, 283(26): 18283-18291. 10.1074/jbc.M801013200 [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Funami K, Matsumoto M, Obuse C, et al. , 2016. 14-3-3-ζ participates in TLR3-mediated TICAM-1 signal-platform formation. Mol Immunol, 73: 60-68. 10.1016/j.molimm.2016.03.010 [DOI] [PubMed] [Google Scholar]
  46. Galluzzi L, Green DR, 2019. Autophagy-independent functions of the autophagy machinery. Cell, 177(7): ‍1682-1699. 10.1016/j.cell.2019.05.026 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Gao D, Wang XD, Jin GY, et al. , 2015. Research progress of Toll-like receptor and ligand complex structure. China J Cell Mol Immunol, 31(4): 553-556(in Chinese). 10.13423/j.cnki.cjcmi.007335 [DOI] [Google Scholar]
  48. Gao JJ, Tian ZX, Yang X, 2020. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends, 14(1): 72-73. 10.5582/bst.2020.01047 [DOI] [PubMed] [Google Scholar]
  49. Geng PL, Song LX, An HJ, et al. , 2016. Toll-like receptor 3 is associated with the risk of HCV infection and HBV-related diseases. Medicine (Baltimore), 95(21): e2302. 10.1097/md.0000000000002302 [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Gong T, Liu L, Jiang W, et al. , 2020. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol, 20(2): 95-112. 10.1038/s41577-019-0215-7 [DOI] [PubMed] [Google Scholar]
  51. Gosu V, Son S, Shin D, et al. , 2019. Insights into the dynamic nature of the dsRNA-bound TLR3 complex. Sci Rep, 9: 3652. 10.1038/s41598-019-39984-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Gowen BB, Hoopes JD, Wong MH, et al. , 2006. TLR3 deletion limits mortality and disease severity due to phlebovirus infection. J Immunol, 177(9): 6301-6307. 10.4049/jimmunol.177.9.6301 [DOI] [PubMed] [Google Scholar]
  53. Guan WJ, Ni ZY, Hu Y, et al. , 2020. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 382(18): 1708-1720. 10.1056/NEJMoa2002032 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Guo BC, Cheng GH, 2007. Modulation of the interferon antiviral response by the TBK1/IKKI adaptor protein TANK. J Biol Chem, 282(16): 11817-11826. 10.1074/jbc.M700017200 [DOI] [PubMed] [Google Scholar]
  55. Han CF, Jin J, Xu S, et al. , 2010. Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b. Nat Immunol, 11(8): 734-742. 10.1038/ni.1908 [DOI] [PubMed] [Google Scholar]
  56. Hardarson HS, Baker JS, Yang Z, et al. , 2007. Toll-like receptor 3 is an essential component of the innate stress response in virus-induced cardiac injury. Am J Physiol Heart Circ Physiol, 292(1): H251-H258. 10.1152/ajpheart.00398.2006 [DOI] [PubMed] [Google Scholar]
  57. Hase K, Contu VR, Kabuta C, et al. , 2020. Cytosolic domain of SIDT2 carries an arginine-rich motif that binds to RNA/DNA and is important for the direct transport of nucleic acids into lysosomes. Autophagy, 16(11): ‍1974-1988. 10.1080/15548627.2020.1712109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. He X, Li Y, Li C, et al. , 2013. USP2a negatively regulates IL-1β‍- and virus-induced NF-κB activation by deubiquitinating TRAF6. J Mol Cell Biol, 5(1): 39-47. 10.1093/jmcb/mjs024 [DOI] [PubMed] [Google Scholar]
  59. Hidaka F, Matsuo S, Muta T, et al. , 2006. A missense mutation of the Toll-like receptor 3 gene in a patient with influenza-associated encephalopathy. Clin Immunol, 119(2): 188-194. 10.1016/j.clim.2006.01.005 [DOI] [PubMed] [Google Scholar]
  60. Honda K, Takaoka A, Taniguchi T, 2006. Type I inteferon gene induction by the interferon regulatory factor family of transcription factors. Immunity, 25(3): 349-360. 10.1016/j.immuni.2006.08.009 [DOI] [PubMed] [Google Scholar]
  61. Hu YH, Zhang Y, Jiang LQ, et al. , 2015. WDFY1 mediates TLR3/4 signaling by recruiting TRIF. EMBO Rep, 16(4): 447-455. 10.15252/embr.201439637 [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Huh HD, Lee E, Shin J, et al. , 2017. STRAP positively regulates TLR3-triggered signaling pathway. Cell Immunol, 318: 55-60. 10.1016/j.cellimm.2017.06.005 [DOI] [PubMed] [Google Scholar]
  63. Huo CY, Jin Y, Zou SM, et al. , 2018. Lethal influenza A virus preferentially activates TLR3 and triggers a severe inflammatory response. Virus Res, 257: 102-112. 10.1016/j.virusres.2018.09.012 [DOI] [PubMed] [Google Scholar]
  64. Ismail S, Ahmad S, Azam SS, 2020. Immunoinformatics characterization of SARS-CoV-2 spike glycoprotein for prioritization of epitope based multivalent peptide vaccine. J Mol Liq, 314: 113612. 10.1016/j.molliq.2020.113612 [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Itoh K, Watanabe A, Funami K, et al. , 2008. The clathrin-mediated endocytic pathway participates in dsRNA-induced IFN-β production. J Immunol, 181(8): ‍5522-5529. 10.4049/jimmunol.181.8.5522 [DOI] [PubMed] [Google Scholar]
  66. Jiang Y, Ye L, Cui Y, et al. , 2017. Effects of Lactobacillus rhamnosus GG on the maturation and differentiation of dendritic cells in rotavirus-infected mice. Benef Microbes, 8(4): 645-656. 10.3920/bm2016.0157 [DOI] [PubMed] [Google Scholar]
  67. Johnsen IB, Nguyen TT, Ringdal M, et al. , 2006. Toll-like receptor 3 associates with c-Src tyrosine kinase on endosomes to initiate antiviral signaling. EMBO J, 25(14): 3335-3346. 10.1038/sj.emboj.7601222 [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Kang JY, Lee JO, 2011. Structural biology of the Toll-like receptor family. Annu Rev Biochem, 80: 917-941. 10.1146/annurev-biochem-052909-141507 [DOI] [PubMed] [Google Scholar]
  69. Karikó K, Bhuyan P, Capodici J, et al. , 2004. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through Toll-like receptor 3. J Immunol, 172(11): 6545-6549. 10.4049/jimmunol.172.11.6545 [DOI] [PubMed] [Google Scholar]
  70. Karikó K, Buckstein M, Ni H, et al. , 2005. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 23(2): 165-175. 10.1016/j.immuni.2005.06.008 [DOI] [PubMed] [Google Scholar]
  71. Karimi-Googheri M, Arababadi MK, 2014. TLR3 plays significant roles against hepatitis B virus. Mol Biol Rep, 41(5): 3279-3286. 10.1007/s11033-014-3190-x [DOI] [PubMed] [Google Scholar]
  72. Kawai T, Akira S, 2007. Signaling to NF-κB by Toll-like receptors. Trends Mol Med, 13(11): 460-469. 10.1016/j.molmed.2007.09.002 [DOI] [PubMed] [Google Scholar]
  73. Kawai T, Akira S, 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol, 11(5): 373-384. 10.1038/ni.1863 [DOI] [PubMed] [Google Scholar]
  74. Kawasaki T, Kawai T, 2014. Toll-like receptor signaling pathways. Front Immunol, 5: 461. 10.3389/fimmu.2014.00461 [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Kayagaki N, Phung Q, Chan S, et al. , 2007. A deubiquitinase that regulates type I interferon production. Science, 318(5856): 1628-1632. 10.1126/science.1145918 [DOI] [PubMed] [Google Scholar]
  76. Kindberg E, Vene S, Mickiene A, et al. , 2011. A functional Toll-like receptor 3 gene (TLR3) may be a risk factor for tick-borne encephalitis virus (TBEV) infection. J Infect Dis, 203(4): 523-528. 10.1093/infdis/jiq082 [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Kleinman ME, Yamada K, Takeda A, et al. , 2008. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature, 452(7187): 591-597. 10.1038/nature06765 [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Kohl B, Granitzka V, Singh A, et al. , 2019. Comparison of backbone dynamics of the p50 dimerization domain of NFκB in the homodimeric transcription factor NFκB1 and in its heterodimeric complex with RelA (p65). Protein Sci, 28(12): 2064-2072. 10.1002/pro.3736 [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Kong KF, Delroux K, Wang XM, et al. , 2008. Dysregulation of TLR3 impairs the innate immune response to West Nile virus in the elderly. J Virol, 82(15): 7613-7623. 10.1128/jvi.00618-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Kramer LD, Styer LM, Ebel GD, 2008. A global perspective on the epidemiology of West Nile virus. Annu Rev Entomol, 53: 61-81. 10.1146/annurev.ento.53.103106.093258 [DOI] [PubMed] [Google Scholar]
  81. Kulka M, Alexopoulou L, Flavell RA, et al. , 2004. Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. J Allergy Clin Immunol, 114(1): 174-182. 10.1016/j.jaci.2004.03.049 [DOI] [PubMed] [Google Scholar]
  82. Kumeta H, Sakakibara H, Enokizono Y, et al. , 2014. The N-terminal domain of TIR domain-containing adaptor molecule-1, TICAM-1. J Biomol NMR, 58(3): 227-230. 10.1007/s10858-014-9819-1 [DOI] [PubMed] [Google Scholar]
  83. Lafaille FG, Pessach IM, Zhang SY, et al. , 2012. Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells. Nature, 491(7426): 769-773. 10.1038/nature11583 [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Langston PK, Nambu A, Jung J, et al. , 2019. Glycerol phosphate shuttle enzyme GPD2 regulates macrophage inflammatory responses. Nat Immunol, 20(9): 1186-1195. 10.1038/s41590-019-0453-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Laporte SA, Scott MGH, 2019. β‍-Arrestins: multitask scaffolds orchestrating the where and when in cell signalling. In: Scott MGH, Laporte SA (Eds.), Beta-Arrestins. Humana Press, New York, p.9-55. 10.1007/978-1-4939-9158-7_2 [DOI] [PubMed] [Google Scholar]
  86. Lee HK, Dunzendorfer S, Soldau K, et al. , 2006. Double-stranded RNA-mediated TLR3 activation is enhanced by CD14. Immunity, 24(2): 153-163. 10.1016/j.immuni.2005.12.012 [DOI] [PubMed] [Google Scholar]
  87. Lee KG, Xu SL, Kang ZH, et al. , 2012. Bruton’s tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response. Proc Natl Acad Sci USA, 109(15): 5791-5796. 10.1073/pnas.1119238109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Lei CQ, Wu X, Zhong X, et al. , 2019. USP19 inhibits TNF-α- and IL-1β-triggered NF-κB activation by deubiquitinating TAK1. J Immunol, 203(1): 259-268. 10.4049/jimmunol.1900083 [DOI] [PubMed] [Google Scholar]
  89. Leonard JN, Ghirlando R, Askins J, et al. , 2008. The TLR3 signaling complex forms by cooperative receptor dimerization. Proc Natl Acad Sci USA, 105(1): 258-263. 10.1073/pnas.0710779105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Leung YHC, Nicholls JM, Ho CK, et al. , 2014. Highly pathogenic avian influenza A H5N1 and pandemic H1N1 virus infections have different phenotypes in Toll-like receptor 3 knockout mice. J Gen Virol, 95(Pt 9): 1870-1879. 10.1099/vir.0.066258-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Li FB, Li Y, Liang HC, et al. , 2018. HECTD3 mediates TRAF3 polyubiquitination and type I interferon induction during bacterial infection. J Clin Invest, 128(9): 4148-4162. 10.1172/jci120406 [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Li K, Li NL, Wei D, et al. , 2012. Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on Toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates. Hepatology, 55(3): 666-675. 10.1002/hep.24763 [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Li ST, Wang LY, Berman M, et al. , 2011. Mapping a dynamic innate immunity protein interaction network regulating type I interferon production. Immunity, 35(3): 426-440. 10.1016/j.immuni.2011.06.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Li WW, Nie Y, Yang Y, et al. , 2020. Ubiquitination of TLR3 by TRIM3 signals its ESCRT-mediated trafficking to the endolysosomes for innate antiviral response. Proc Natl Acad Sci USA, 117(38): 23707-23716. 10.1073/pnas.2002472117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Limmon GV, Arredouani M, McCann KL, et al. , 2008. Scavenger receptor class-A is a novel cell surface receptor for double-stranded RNA. FASEB J, 22(1): 159-167. 10.1096/fj.07-8348com [DOI] [PubMed] [Google Scholar]
  96. Liu GK, 2019. The Effect of Ubiquitin Ligase Nedd4l on Toll-like Receptor Signaling Transduction of Macrophage. PhD Dissemination, the Second Military Medical University, Shanghai, China(in Chinese). [Google Scholar]
  97. Liu GQ, Gack MU, 2020. Distinct and orchestrated functions of RNA sensors in innate immunity. Immunity, 53(1): 26-42. 10.1016/j.immuni.2020.03.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. Liu GQ, Lu Y, Thulasi Raman SN, et al. , 2018. Nuclear-resident RIG-I senses viral replication inducing antiviral immunity. Nat Commun, 9: 3199. 10.1038/s41467-018-05745-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Liu L, Botos I, Wang Y, et al. , 2008. Structural basis of Toll-like receptor 3 signaling with double-stranded RNA. Science, 320(5874): 379-381. 10.1126/science.1155406 [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Liu SQ, Cai X, Wu JX, et al. , 2015. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science, 347(6227): aaa2630. 10.1126/science.aaa2630 [DOI] [PubMed] [Google Scholar]
  101. Loo YM, Gale M, 2011. Immune signaling by RIG-I-like receptors. Immunity, 34(5): 680-692. 10.1016/j.immuni.2011.05.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Lu D, Song J, Sun YZ, et al. , 2018. Mutations of deubiquitinase OTUD1 are associated with autoimmune disorders. J Autoimmun, 94: 156-165. 10.1016/j.jaut.2018.07.019 [DOI] [PubMed] [Google Scholar]
  103. Luo JQ, Obmolova G, Malia TJ, et al. , 2012. Lateral clustering of TLR3: dsRNA signaling units revealed by TLR3ecd: 3fabs quaternary structure. J Mol Biol, 421(1): 112-124. 10.1016/j.jmb.2012.05.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Luo L, Curson JEB, Liu LP, et al. , 2020. SCIMP is a universal Toll-like receptor adaptor in macrophages. J Leukoc Biol, 107(2): 251-262. 10.1002/jlb.2ma0819-138rr [DOI] [PubMed] [Google Scholar]
  105. Mahita J, Sowdhamini R, 2017. Integrative modelling of TIR domain-containing adaptor molecule inducing interferon-‍β (TRIF) provides insights into its autoinhibited state. Biol Direct, 12: 9. 10.1186/s13062-017-0179-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Mahita J, Sowdhamini R, 2018. Investigating the effect of key mutations on the conformational dynamics of Toll-like receptor dimers through molecular dynamics simulations and protein structure networks. Proteins, 86(4): 475-490. 10.1002/prot.25467 [DOI] [PubMed] [Google Scholar]
  107. Maire M, Parent R, Morand AL, et al. , 2008. Characterization of the double-stranded RNA responses in human liver progenitor cells. Biochem Biophys Res Commun, 368(3): 556-562. 10.1016/j.bbrc.2008.01.123 [DOI] [PubMed] [Google Scholar]
  108. Marshall JS, Portales-Cervantes L, Leong E, 2019. Mast cell responses to viruses and pathogen products. Int J Mol Sci, 20(17): 4241. 10.3390/ijms20174241 [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Martin-Gayo E, Yu XG, 2017. Dendritic cell immune responses in HIV-1 controllers. Curr HIV/AIDS Rep, 14(1): 1-7. 10.1007/s11904-017-0345-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. Matsumoto M, Funami K, Tanabe M, et al. , 2003. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol, 171(6): 3154-3162. 10.4049/jimmunol.171.6.3154 [DOI] [PubMed] [Google Scholar]
  111. Matsumoto M, Oshiumi H, Seya T, 2011. Antiviral responses induced by the TLR3 pathway. Rev Med Virol, 21(2): 67-77. 10.1002/rmv.680 [DOI] [PubMed] [Google Scholar]
  112. Matsumoto M, Takeda Y, Seya T, 2020. Targeting Toll-like receptor 3 in dendritic cells for cancer immunotherapy. Expert Opin Biol Ther, 20(8): 937-946. 10.1080/14712598.2020.1749260 [DOI] [PubMed] [Google Scholar]
  113. Meng D, Huo CY, Wang M, et al. , 2016. Influenza a viruses replicate productively in mouse mastocytoma cells (P815) and trigger pro-inflammatory cytokine and chemokine production through TLR3 signaling pathway. Front Microbiol, 7: 2130. 10.3389/fmicb.2016.02130 [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. Meylan E, Burns K, Hofmann K, et al. , 2004. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-‍κB activation. Nat Immunol, 5(5): 503-507. 10.1038/ni1061 [DOI] [PubMed] [Google Scholar]
  115. Mickienė A, Pakalnienė J, Nordgren J, et al. , 2014. Polymorphisms in chemokine receptor 5 and Toll-like receptor 3 genes are risk factors for clinical tick-borne encephalitis in the Lithuanian population. PLoS ONE, 9(9): e106798. 10.1371/journal.pone.0106798 [DOI] [PMC free article] [PubMed] [Google Scholar]
  116. Mielcarska MB, Bossowska-Nowicka M, Toka FN, 2018. Functional failure of TLR3 and its signaling components contribute to herpes simplex encephalitis. J Neuroimmunol, 316: 65-73. 10.1016/j.jneuroim.2017.12.011 [DOI] [PubMed] [Google Scholar]
  117. Mineev KS, Goncharuk SA, Arseniev AS, 2014. Toll-like receptor 3 transmembrane domain is able to perform various homotypic interactions: an NMR structural study. FEBS Lett, 588(21): 3802-3807. 10.1016/j.febslet.2014.08.031 [DOI] [PubMed] [Google Scholar]
  118. Mitchell S, Vargas J, Hoffmann A, 2016. Signaling via the NFκB system. WIREs Syst Biol Med, 8(3): 227-241. 10.1002/wsbm.1331 [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. Mortaz E, Adcock IM, Abedini A, et al. , 2017. The role of pattern recognition receptors in lung sarcoidosis. Eur J Pharmacol, 808: 44-48. 10.1016/j.ejphar.2017.01.020 [DOI] [PubMed] [Google Scholar]
  120. Mosaad YM, Metwally SS, Farag RE, et al. , 2019. Association between Toll-like receptor 3 (TLR3) rs3775290, TLR7 rs179008, TLR9 rs352140 and chronic HCV. Immunol Invest, 48(3): 321-332. 10.1080/08820139.2018.1527851 [DOI] [PubMed] [Google Scholar]
  121. Negishi H, Osawa T, Ogami K, et al. , 2008. A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity. Proc Natl Acad Sci USA, 105(51): 20446-20451. 10.1073/pnas.0810372105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  122. Nguyen H, Gazy N, Venketaraman V, 2020. A role of intracellular Toll-like receptors (3, 7, and 9) in response to Mycobacterium tuberculosis and co-infection with HIV. Int J Mol Sci, 21(17): 6148. 10.3390/ijms21176148 [DOI] [PMC free article] [PubMed] [Google Scholar]
  123. Nguyen VP, Chen J, Petrus MN, et al. , 2014. A new domain in the Toll/IL-1R domain-containing adaptor inducing interferon-‍β factor protein amino terminus is important for tumor necrosis factor-‍α receptor-associated factor 3 association, protein stabilization and interferon signaling. J Innate Immun, 6(3): 377-393. 10.1159/000356408 [DOI] [PMC free article] [PubMed] [Google Scholar]
  124. Ondondo BO, Brunham RC, Harrison WG, et al. , 2009. Frequency and magnitude of Chlamydia trachomatis elementary body- and heat shock protein 60-stimulated interferon γ responses in peripheral blood mononuclear cells and endometrial biopsy samples from women with high exposure to infection. J Infect Dis, 199(12): ‍1771-1779. 10.1086/599095 [DOI] [PubMed] [Google Scholar]
  125. Oshiumi H, Matsumoto M, Funami K, et al. , 2003. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-‍β induction. Nat Immunol, 4(2): 161-167. 10.1038/ni886 [DOI] [PubMed] [Google Scholar]
  126. Oshiumi H, Okamoto M, Fujii K, et al. , 2011. The TLR3/TICAM-1 pathway is mandatory for innate immune responses to poliovirus infection. J Immunol, 187(10): 5320-5327. 10.4049/jimmunol.1101503 [DOI] [PubMed] [Google Scholar]
  127. Pabo CO, Sauer RT, 1984. Protein-DNA recognition. Annu Rev Biochem, 53: 293-321. 10.1146/annurev.bi.53.070184.001453 [DOI] [PubMed] [Google Scholar]
  128. Park GB, Hur DY, Kim YS, et al. , 2015. TLR3/TRIF signalling pathway regulates IL-32 and IFN-‍β secretion through activation of RIP-1 and TRAF in the human cornea. J Cell Mol Med, 19(5): 1042-1054. 10.1111/jcmm.12495 [DOI] [PMC free article] [PubMed] [Google Scholar]
  129. Patel S, Sinigaglia A, Barzon L, et al. , 2019. Role of NS1 and TLR3 in pathogenesis and immunity of WNV. Viruses, 11(7): 603. 10.3390/v11070603 [DOI] [PMC free article] [PubMed] [Google Scholar]
  130. Patra MC, Batool M, Haseeb M, et al. , 2020. A computational probe into the structure and dynamics of the full-length Toll-like receptor 3 in a phospholipid bilayer. Int J Mol Sci, 21(8): 2857. 10.3390/ijms21082857 [DOI] [PMC free article] [PubMed] [Google Scholar]
  131. Peisley A, Hur S, 2013. Multi-level regulation of cellular recognition of viral dsRNA. Cell Mol Life Sci, 70(11): 1949-1963. 10.1007/s00018-012-1149-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  132. Pelka K, Bertheloot D, Reimer E, et al. , 2018. The chaperone UNC93B1 regulates Toll-like receptor stability independently of endosomal TLR transport. Immunity, 48(5): 911-922.e7. 10.1016/j.immuni.2018.04.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  133. Peng J, Yuan Q, Lin B, et al. , 2010. SARM inhibits both TRIF- and MyD88-mediated AP-1 activation. Eur J Immunol, 40(6): 1738-1747. 10.1002/eji.200940034 [DOI] [PubMed] [Google Scholar]
  134. Perales-Linares R, Navas-Martin S, 2013. Toll-like receptor 3 in viral pathogenesis: friend or foe? Immunology, 140(2): 153-167. 10.1111/imm.12143 [DOI] [PMC free article] [PubMed] [Google Scholar]
  135. Piliponsky AM, Romani L, 2018. The contribution of mast cells to bacterial and fungal infection immunity. Immunol Rev, 282(1): 188-197. 10.1111/imr.12623 [DOI] [PMC free article] [PubMed] [Google Scholar]
  136. Pott J, Stockinger S, Torow N, et al. , 2012. Age-dependent TLR3 expression of the intestinal epithelium contributes to rotavirus susceptibility. PLoS Pathog, 8(5): e1002670. 10.1371/journal.ppat.1002670 [DOI] [PMC free article] [PubMed] [Google Scholar]
  137. Prasad K, Khatoon F, Rashid S, et al. , 2020. Targeting hub genes and pathways of innate immune response in COVID-19: a network biology perspective. Int J Biol Macromol, 163: 1-8. 10.1016/j.ijbiomac.2020.06.228 [DOI] [PMC free article] [PubMed] [Google Scholar]
  138. Rai RC, 2020. Host inflammatory responses to intracellular invaders: review study. Life Sci, 240: 117084. 10.1016/j.lfs.2019.117084 [DOI] [PubMed] [Google Scholar]
  139. Rehwinkel J, Gack MU, 2020. RIG-I-like receptors: their regulation and roles in RNA sensing. Nat Rev Immunol, 20(9): 537-551. 10.1038/s41577-020-0288-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  140. Ryo A, Suizu F, Yoshida Y, et al. , 2003. Regulation of NF-κB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/Rela. Mol Cell, 12(6): 1413-1426. 10.1016/s1097-2765(03)00490-8 [DOI] [PubMed] [Google Scholar]
  141. Ryzhakov G, Randow F, 2007. SINTBAD, a novel component of innate antiviral immunity, shares a TBK1-binding domain with NAP1 and TANK. EMBO J, 26(13): 3180-3190. 10.1038/sj.emboj.7601743 [DOI] [PMC free article] [PubMed] [Google Scholar]
  142. Saitoh T, Yamamoto M, Miyagishi M, et al. , 2005. A20 is a negative regulator of IFN regulatory factor 3 signaling. J Immunol, 174(3): 1507-1512. 10.4049/jimmunol.174.3.1507 [DOI] [PubMed] [Google Scholar]
  143. Salio M, Cerundolo V, 2005. Viral immunity: cross-priming with the help of TLR3. Curr Biol, 15(9): R336-R339. 10.1016/j.cub.2005.04.025 [DOI] [PubMed] [Google Scholar]
  144. Sancho-Shimizu V, de Diego RP, Jouanguy E, et al. , 2011. Inborn errors of anti-viral interferon immunity in humans. Curr Opin Virol, 1(6): 487-496. 10.1016/j.coviro.2011.10.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  145. Sander WJ, O'Neill HG, Pohl CH, 2017. Prostaglandin E2 as a modulator of viral infections. Front Physiol, 8: 89. 10.3389/fphys.2017.00089 [DOI] [PMC free article] [PubMed] [Google Scholar]
  146. Sarkar SN, Smith HL, Rowe TM, et al. , 2003. Double-stranded RNA signaling by Toll-like receptor 3 requires specific tyrosine residues in its cytoplasmic domain. J Biol Chem, 278(7): 4393-4396. 10.1074/jbc.C200655200 [DOI] [PubMed] [Google Scholar]
  147. Sarkar SN, Peters KL, Elco CP, et al. , 2004. Novel roles of TLR3 tyrosine phosphorylation and PI3 kinase in double-stranded RNA signaling. Nat Struct Mol Biol, 11(11): 1060-1067. 10.1038/nsmb847 [DOI] [PubMed] [Google Scholar]
  148. Sasai M, Tatematsu M, Oshiumi H, et al. , 2010. Direct binding of TRAF2 and TRAF6 to TICAM-1/TRIF adaptor participates in activation of the Toll-like receptor 3/4 pathway. Mol Immunol, 47(6): 1283-1291. 10.1016/j.molimm.2009.12.002 [DOI] [PubMed] [Google Scholar]
  149. Sato R, Kato A, Chimura T, et al. , 2018. Combating herpesvirus encephalitis by potentiating a TLR3‍-‍mTORC2 axis. Nat Immunol, 19(10): 1071-1082. 10.1038/s41590-018-0203-2 [DOI] [PubMed] [Google Scholar]
  150. Saxena M, Sabado RL, La Mar M, et al. , 2019. Poly-ICLC, a TLR3 agonist, induces transient innate immune responses in patients with treated HIV-infection: a randomized double-blinded placebo controlled trial. Front Immunol, 10: 725. 10.3389/fimmu.2019.00725 [DOI] [PMC free article] [PubMed] [Google Scholar]
  151. Schmid S, Sachs D, Tenoever BR, 2014. Mitogen-activated protein kinase-mediated licensing of interferon regulatory factor 3/7 reinforces the cell response to virus. J Biol Chem, 289(1): 299-311. 10.1074/jbc.M113.519934 [DOI] [PMC free article] [PubMed] [Google Scholar]
  152. Schröder M, Bowie AG, 2005. TLR3 in antiviral immunity: key player or bystander? Trends Immunol, 26(9): ‍462-468. 10.1016/j.it.2005.07.002 [DOI] [PubMed] [Google Scholar]
  153. Sesti-Costa R, Françozo MCS, Silva GK, et al. , 2017. TLR3 is required for survival following Coxsackievirus B3 infection by driving T lymphocyte activation and polarization: the role of dendritic cells. PLoS ONE, 12(10): e0185819. 10.1371/journal.pone.0185819 [DOI] [PMC free article] [PubMed] [Google Scholar]
  154. Shin C, Ito Y, Ichikawa S, et al. , 2017. MKRN2 is a novel ubiquitin E3 ligase for the p65 subunit of NF-‍κB and negatively regulates inflammatory responses. Sci Rep, 7: 46097. 10.1038/srep46097 [DOI] [PMC free article] [PubMed] [Google Scholar]
  155. Singh D, Qi RS, Jordan JL, et al. , 2013. The human antimicrobial peptide LL-37, but not the mouse ortholog, mCRAMP, can stimulate signaling by poly(I: C) through a FPRL1-dependent pathway. J Biol Chem, 288(12): 8258-8268. 10.1074/jbc.M112.440883 [DOI] [PMC free article] [PubMed] [Google Scholar]
  156. Singh S, Pandey K, Rathore YS, et al. , 2014. A communication network within the cytoplasmic domain of Toll-like receptors has remained conserved during evolution. J Biomol Struct Dyn, 32(5): 694-700. 10.1080/07391102.2013.787545 [DOI] [PubMed] [Google Scholar]
  157. Sioud M, 2006. Innate sensing of self and non-self RNAs by Toll-like receptors. Trends Mol Med, 12(4): 167-176. 10.1016/j.molmed.2006.02.004 [DOI] [PubMed] [Google Scholar]
  158. Song GH, Liu BY, Li ZH, et al. , 2016. E3 ubiquitin ligase RNF128 promotes innate antiviral immunity through K63-linked ubiquitination of TBK1. Nat Immunol, 17(12): 1342-1351. 10.1038/ni.3588 [DOI] [PubMed] [Google Scholar]
  159. Song XQ, Liu S, Wang WD, et al. , 2020. E3 ubiquitin ligase RNF170 inhibits innate immune responses by targeting and degrading TLR3 in murine cells. Cell Mol Immunol, 17(8): 865-874. 10.1038/s41423-019-0236-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  160. Søreng K, Neufeld TP, Simonsen A, 2018. Membrane trafficking in autophagy. Int Rev Cell Mol Biol, 336: 1-92. 10.1016/bs.ircmb.2017.07.001 [DOI] [PubMed] [Google Scholar]
  161. Sorokin AV, Kim ER, Ovchinnikov LP, 2009. Proteasome system of protein degradation and processing. Biochemistry (Mosc), 74(13): 1411-1442. 10.1134/s000629790913001x [DOI] [PubMed] [Google Scholar]
  162. Soto JA, Gálvez NMS, Andrade CA, et al. , 2020. The role of dendritic cells during infections caused by highly prevalent viruses. Front Immunol, 11: 1513. 10.3389/fimmu.2020.01513 [DOI] [PMC free article] [PubMed] [Google Scholar]
  163. Spearman CW, Dusheiko GM, Hellard M, et al. , 2019. Hepatitis C. Lancet, 394(10207): 1451-1466. 10.1016/s0140-6736(19)32320-7 [DOI] [PubMed] [Google Scholar]
  164. Sun LJ, Wu JX, Du FH, et al. , 2013. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science, 339(6121): 786-791. 10.1126/science.1232458 [DOI] [PMC free article] [PubMed] [Google Scholar]
  165. Tabeta K, Hoebe K, Janssen EM, et al. , 2006. The unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat Immunol, 7(2): 156-164. 10.1038/ni1297 [DOI] [PubMed] [Google Scholar]
  166. Takahashi T, Kulkarni NN, Lee EY, et al. , 2018. Cathelicidin promotes inflammation by enabling binding of self-RNA to cell surface scavenger receptors. Sci Rep, 8: 4032. 10.1038/s41598-018-22409-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  167. Takeda K, Akira S, 2015. Toll-like receptors. Curr Protoc Immunol, 109: 14.12.1-14.12.10. 10.1002/0471142735.im1412s109 [DOI] [PubMed] [Google Scholar]
  168. Tan YH, Kagan JC, 2019. Innate immune signaling organelles display natural and programmable signaling flexibility. Cell, 177(2): 384-398.e11. 10.1016/j.cell.2019.01.039 [DOI] [PMC free article] [PubMed] [Google Scholar]
  169. Tatematsu M, Ishii A, Oshiumi H, et al. , 2010. A molecular mechanism for Toll-IL-1 receptor domain-containing adaptor molecule-1-mediated IRF-3 activation. J Biol Chem, 285(26): 20128-20136. 10.1074/jbc.M109.099101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  170. Tavora B, Mederer T, Wessel KJ, et al. , 2020. Tumoural activation of TLR3‍-‍SLIT2 axis in endothelium drives metastasis. Nature, 586(7828): 299-304. 10.1038/s41586-020-2774-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  171. ETTL Tjwa, van Oord GW, Biesta PJ, et al. , 2012. Restoration of TLR3-activated myeloid dendritic cell activity leads to improved natural killer cell function in chronic hepatitis B virus infection. J Virol, 86(8): 4102-4109. 10.1128/jvi.07000-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  172. Topping KD, Kelly DG, 2019. Investigation of binding characteristics of immobilized Toll-like receptor 3 with poly(I: C) for potential biosensor application. Anal Biochem, 564-565: 133-140. 10.1016/j.ab.2018.05.023 [DOI] [PubMed] [Google Scholar]
  173. Town T, Jeng D, Alexopoulou L, et al. , 2006. Microglia recognize double-stranded RNA via TLR3. J Immunol, 176(6): 3804-3812. 10.4049/jimmunol.176.6.3804 [DOI] [PubMed] [Google Scholar]
  174. Tseng PH, Matsuzawa A, Zhang WZ, et al. , 2010. Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nat Immunol, 11(1): 70-75. 10.1038/ni.1819 [DOI] [PMC free article] [PubMed] [Google Scholar]
  175. Uehata T, Takeuchi O, 2020. RNA recognition and immunity‍–innate immune sensing and its posttranscriptional regulation mechanisms. Cells, 9(7): 1701. 10.3390/cells9071701 [DOI] [PMC free article] [PubMed] [Google Scholar]
  176. Unterholzner L, Keating SE, Baran M, et al. , 2010. IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol, 11(11): 997-1004. 10.1038/ni.1932 [DOI] [PMC free article] [PubMed] [Google Scholar]
  177. Wang K, Liu HL, He YL, et al. , 2010. Correlation of TLR1-10 expression in peripheral blood mononuclear cells with chronic hepatitis B and chronic hepatitis B-related liver failure. Hum Immunol, 71(10): 950-956. 10.1016/j.humimm.2010.07.013 [DOI] [PubMed] [Google Scholar]
  178. Wang L, Wen MY, Cao XT, 2019. Nuclear hnRNPA2B1 initiates and amplifies the innate immune response to DNA viruses. Science, 365(6454): eaav0758. 10.1126/science.aav0758 [DOI] [PubMed] [Google Scholar]
  179. Wang P, Zhao W, Zhao K, et al. , 2015. TRIM26 negatively regulates interferon-‍β production and antiviral response through polyubiquitination and degradation of nuclear IRF3. PLoS Pathog, 11(3): e1004726. 10.1371/journal.ppat.1004726 [DOI] [PMC free article] [PubMed] [Google Scholar]
  180. Wang T, Town T, Alexopoulou L, et al. , 2004. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med, 10(12): 1366-1373. 10.1038/nm1140 [DOI] [PubMed] [Google Scholar]
  181. Wang Y, Liu L, Davies DR, et al. , 2010. Dimerization of Toll-like receptor 3 (TLR3) is required for ligand binding. J Biol Chem, 285(47): 36836-36841. 10.1074/jbc.M110.167973 [DOI] [PMC free article] [PubMed] [Google Scholar]
  182. Wang Y, Yuan SC, Jia X, et al. , 2019. Mitochondria-localised ZNFX1 functions as a dsRNA sensor to initiate antiviral responses through MAVs. Nat Cell Biol, 21(11): ‍1346-1356. 10.1038/s41556-019-0416-0 [DOI] [PubMed] [Google Scholar]
  183. Wang YY, Tang YW, Teng L, et al. , 2006. Association of β-arrestin and TRAF6 negatively regulates Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol, 7(2): ‍139-147. 10.1038/ni1294 [DOI] [PubMed] [Google Scholar]
  184. Watanabe A, Tatematsu M, Saeki K, et al. , 2011. Raftlin is involved in the nucleocapture complex to induce poly(I: C)-mediated TLR3 activation. J Biol Chem, 286(12): 10702-10711. 10.1074/jbc.M110.185793 [DOI] [PMC free article] [PubMed] [Google Scholar]
  185. Weber C, Müller C, Podszuweit A, et al. , 2012. Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects). Immunology, 136(1): 64-77. 10.1111/j.1365-2567.2012.03559.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  186. Wilson JR, de Sessions PF, Leon MA, et al. , 2008. West Nile virus nonstructural protein 1 inhibits TLR3 signal transduction. J Virol, 82(17): 8262-8271. 10.1128/jvi.00226-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
  187. Witczak P, Brzezińska-Błaszczyk E, Agier J, 2020. The response of tissue mast cells to TLR3 ligand poly(I: ‍C) treatment. J Immunol Res, 2020: 2140694. 10.1155/2020/2140694 [DOI] [PMC free article] [PubMed] [Google Scholar]
  188. Witherow DS, Garrison TR, Miller WE, et al. , 2004. β-Arrestin inhibits NF-κB activity by means of its interaction with the NF‍-‍κB inhibitor IκBα. Proc Natl Acad Sci USA, 101(23): 8603-8607. 10.1073/pnas.0402851101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  189. Wu F, Zhao S, Yu B, et al. , 2020. A new coronavirus associated with human respiratory disease in China. Nature, 579(7798): 265-269. 10.1038/s41586-020-2008-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  190. Wu FY, Niu ZM, Zhou B, et al. , 2019. PSMB1 negatively regulates the innate antiviral immunity by facilitating degradation of IKK-ε. Viruses, 11(2): 99. 10.3390/v11020099 [DOI] [PMC free article] [PubMed] [Google Scholar]
  191. Wu HF, Liu HS, Zhao XY, et al. , 2020. IKIP negatively regulates NF-κB activation and inflammation through inhibition of IKKα/β phosphorylation. J Immunol, 204(2): 418-427. 10.4049/jimmunol.1900626 [DOI] [PubMed] [Google Scholar]
  192. Wu JX, Chen ZJ, 2014. Innate immune sensing and signaling of cytosolic nucleic acids. Annu Rev Immunol, 32: 461-488. 10.1146/annurev-immunol-032713-120156 [DOI] [PubMed] [Google Scholar]
  193. Wu X, Lei CQ, Xia T, et al. , 2019. Regulation of TRIF-mediated innate immune response by K27-linked polyubiquitination and deubiquitination. Nat Commun, 10: 4115. 10.1038/s41467-019-12145-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  194. Xing JJ, Weng LY, Yuan B, et al. , 2016. Identification of a role for TRIM29 in the control of innate immunity in the respiratory tract. Nat Immunol, 17(12): 1373-1380. 10.1038/ni.3580 [DOI] [PMC free article] [PubMed] [Google Scholar]
  195. Xue QH, Zhou Z, Lei XB, et al. , 2012. TRIM38 negatively regulates TLR3-mediated IFN-‍β signaling by targeting TRIF for degradation. PLoS ONE, 7(10): e46825. 10.1371/journal.pone.0046825 [DOI] [PMC free article] [PubMed] [Google Scholar]
  196. Yamashita M, Chattopadhyay S, Fensterl V, et al. , 2012. Epidermal growth factor receptor is essential for Toll-like receptor 3 signaling. Sci Signal, 5(233): ra50. 10.1126/scisignal.2002581 [DOI] [PMC free article] [PubMed] [Google Scholar]
  197. Yang Q, Shu HB, 2020. Deciphering the pathways to antiviral innate immunity and inflammation. Adv Immunol, 145: 1-36. 10.1016/bs.ai.2019.11.001 [DOI] [PubMed] [Google Scholar]
  198. Yang Y, Liao B, Wang SY, et al. , 2013. E3 ligase WWP2 negatively regulates TLR3-mediated innate immune response by targeting TRIF for ubiquitination and degradation. Proc Natl Acad Sci USA, 110(13): 5115-5120. 10.1073/pnas.1220271110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  199. Yang Y, Wang SY, Huang ZF, et al. , 2016. The RNA-binding protein Mex3B is a coreceptor of Toll-like receptor 3 in innate antiviral response. Cell Res, 26(3): 288-303. 10.1038/cr.2016.16 [DOI] [PMC free article] [PubMed] [Google Scholar]
  200. Ye W, Hu MM, Lei CQ, et al. , 2017. TRIM8 negatively regulates TLR3/4-mediated innate immune response by blocking TRIF-TBK1 interaction. J Immunol, 199(5): 1856-1864. 10.4049/jimmunol.1601647 [DOI] [PubMed] [Google Scholar]
  201. Yu YX, Hayward GS, 2010. The ubiquitin E3 ligase RAUL negatively regulates type I interferon through ubiquitination of the transcription factors IRF7 and IRF3. Immunity, 33(6): 863-877. 10.1016/j.immuni.2010.11.027 [DOI] [PMC free article] [PubMed] [Google Scholar]
  202. Yuan X, Gajan A, Chu Q, et al. , 2018. Developing TRAIL/TRAIL death receptor-based cancer therapies. Cancer Metastasis Rev, 37(4): 733-748. 10.1007/s10555-018-9728-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  203. Yuk JM, Shin DM, Lee HM, et al. , 2011. The orphan nuclear receptor SHP acts as a negative regulator in inflammatory signaling triggered by Toll-like receptors. Nat Immunol, 12(8): 742-751. 10.1038/ni.2064 [DOI] [PubMed] [Google Scholar]
  204. Zang R, Lian H, Zhong X, et al. , 2020. ZCCHC3 modulates TLR3-mediated signaling by promoting recruitment of TRIF to TLR3. J Mol Cell Biol, 12(4): 251-262. 10.1093/jmcb/mjaa004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  205. Zeng WW, Xu M, Liu SQ, et al. , 2009. Key role of Ubc5 and lysine-63 polyubiquitination in viral activation of IRF3. Mol Cell, 36(2): 315-325. 10.1016/j.molcel.2009.09.037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  206. Zhang JY, Shen BF, 2011. SHP limits TLR signaling, an inducible transcriptional corepressor. Cell Mol Immunol, 8(6): 445-446. 10.1038/cmi.2011.31 [DOI] [PMC free article] [PubMed] [Google Scholar]
  207. Zhang L, Zhao XY, Zhang M, et al. , 2014. Ubiquitin-specific protease 2b negatively regulates IFN-β production and antiviral activity by targeting TANK-binding kinase 1. J Immunol, 193(5): 2230-2237. 10.4049/jimmunol.1302634 [DOI] [PubMed] [Google Scholar]
  208. Zhang LY, Xiang WP, Wang GL, et al. , 2016. Interferon β (IFN-‍β) production during the double-stranded RNA (dsRNA) response in hepatocytes involves coordinated and feedforward signaling through Toll-like receptor 3 (TLR3), RNA-dependent protein kinase (PKR), inducible nitric oxide synthase (iNOS), and Src protein. J Biol Chem, 291(29): 15093-15107. 10.1074/jbc.M116.717942 [DOI] [PMC free article] [PubMed] [Google Scholar]
  209. Zhang M, Wang LJ, Zhao XY, et al. , 2012. TRAF-interacting protein (TRIP) negatively regulates IFN-‍β production and antiviral response by promoting proteasomal degradation of TANK-binding kinase 1. J Exp Med, 209(10): 1703-1711. 10.1084/jem.20120024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  210. Zhang Q, Bastard P, Liu ZY, et al. , 2020. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 370(6515): eabd4570. 10.1126/science.abd4570 [DOI] [PMC free article] [PubMed] [Google Scholar]
  211. Zhang SY, Jouanguy E, Ugolini S, et al. , 2007. TLR3 deficiency in patients with herpes simplex encephalitis. Science, 317(5844): 1522-1527. 10.1126/science.1139522 [DOI] [PubMed] [Google Scholar]
  212. Zhang ZQ, Kim T, Bao MS, et al. , 2011. DDX1, DDX21, and DHX36 helicases form a complex with the adaptor molecule TRIF to sense dsRNA in dendritic cells. Immunity, 34(6): 866-878. 10.1016/j.immuni.2011.03.027 [DOI] [PMC free article] [PubMed] [Google Scholar]
  213. Zhao BY, Shu C, Gao XS, et al. , 2016. Structural basis for concerted recruitment and activation of IRF-3 by innate immune adaptor proteins. Proc Natl Acad Sci USA, 113(24): E3403-E3412. 10.1073/pnas.1603269113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  214. Zhao XB, Zhu HH, Yu J, et al. , 2016. c-Cbl-mediated ubiquitination of IRF3 negatively regulates IFN-‍β production and cellular antiviral response. Cell Signal, 28(11): 1683-1693. 10.1016/j.cellsig.2016.08.002 [DOI] [PubMed] [Google Scholar]
  215. Zheng H, Li Q, Chen R, et al. , 2013. The dual-specificity phosphatase DUSP14 negatively regulates tumor necrosis factor- and interleukin-1-induced nuclear factor-κB activation by dephosphorylating the protein kinase TAK1. J Biol Chem, 288(2): 819-825. 10.1074/jbc.M112.412643 [DOI] [PMC free article] [PubMed] [Google Scholar]
  216. Zheng QL, Hou J, Zhou Y, et al. , 2015. Siglec1 suppresses antiviral innate immune response by inducing TBK1 degradation via the ubiquitin ligase TRIM27. Cell Res, 25(10): 1121-1136. 10.1038/cr.2015.108 [DOI] [PMC free article] [PubMed] [Google Scholar]
  217. Zheng Y, Gao CJ, 2020. Fine-tuning of antiviral innate immunity by ubiquitination. Adv Immunol, 145: 95-128. 10.1016/bs.ai.2019.11.004 [DOI] [PubMed] [Google Scholar]
  218. Zhong X, Feng L, Xu WH, et al. , 2020. The zinc-finger protein ZFYVE1 modulates TLR3-mediated signaling by facilitating TLR3 ligand binding. Cell Mol Immunol, 17(7): 741-752. 10.1038/s41423-019-0265-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  219. Zhou RY, Zhang Q, Xu PL, 2020. TBK1, a central kinase in innate immune sensing of nucleic acids and beyond. Acta Biochim Biophys Sin, 52(7): 757-767. 10.1093/abbs/gmaa051 [DOI] [PubMed] [Google Scholar]
  220. Zhou Y, Wang X, Sun L, et al. , 2016. Toll-like receptor 3-activated macrophages confer anti-HCV activity to hepatocytes through exosomes. FASEB J, 30(12): 4132-4140. 10.1096/fj.201600696R [DOI] [PMC free article] [PubMed] [Google Scholar]
  221. Zhu S, Wang G, Lei XQ, et al. , 2016. Mex3B: a coreceptor to present dsRNA to TLR3. Cell Res, 26(4): 391-392. 10.1038/cr.2016.29 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Zhejiang University. Science. B are provided here courtesy of Zhejiang University Press

RESOURCES